


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:59Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406199" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406199</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="b344783087" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406199</article-id><article-id pub-id-type="pmcid-ver">PMC12406199.1</article-id><article-id pub-id-type="pmcaid">12406199</article-id><article-id pub-id-type="pmcaiid">12406199</article-id><article-id pub-id-type="pmid">40815226</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c01008</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>NanoDSF Screening
for Anti-tubulin Agents Uncovers
New Structure&#8211;Activity Insights</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e22-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7590922</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0445-2667</contrib-id><name name-style="western"><surname>Baksheeva</surname><given-names initials="V">Viktoriia</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7590923</contrib-id><name name-style="western"><surname>La Rocca</surname><given-names initials="R">Romain</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7590924</contrib-id><name name-style="western"><surname>Allegro</surname><given-names initials="D">Diane</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2915003</contrib-id><name name-style="western"><surname>Derviaux</surname><given-names initials="C">Carine</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7189858</contrib-id><name name-style="western"><surname>Pasquier</surname><given-names initials="E">Eddy</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3721858</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5580-0588</contrib-id><name name-style="western"><surname>Roche</surname><given-names initials="P">Philippe</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">66673</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8101-7901</contrib-id><name name-style="western"><surname>Morelli</surname><given-names initials="X">Xavier</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6927269</contrib-id><name name-style="western"><surname>Devred</surname><given-names initials="F">Fran&#231;ois</given-names></name><xref rid="aff1" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">3177854</contrib-id><name name-style="western"><surname>Golovin</surname><given-names initials="AV">Andrey V.</given-names></name><xref rid="aff4" ref-type="aff"/><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7495374</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8622-8836</contrib-id><name name-style="western"><surname>Tsvetkov</surname><given-names initials="PO">Philipp O.</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/><xref rid="aff3" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">CNRS,
INP, Inst Neurophysiopathol</institution>, <institution>Aix-Marseille
Univ</institution>, <postal-code>13005</postal-code>
<city>Marseille</city>, <country country="FR">France</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">CNRS,
INSERM, Institut Paoli Calmettes</institution>, <institution>CRCM,
Centre de Recherche en Canc&#233;rologie de Marseille, Aix-Marseille
Univ</institution>, <postal-code>13009</postal-code>
<city>Marseille</city>, <country country="FR">France</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">PINT,
Plateforme Interactions mol&#233;culaires Timone, Facult&#233;
des Sciences M&#233;dicales et Param&#233;dicales</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">128791</institution-id><institution>Aix-Marseille Univ</institution></institution-wrap>, <postal-code>13005</postal-code>
<city>Marseille</city>, <country country="FR">France</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution content-type="dept">Faculty
of Bioengineering and Bioinformatics, Belozersky Institute of Physico-Chemical
Biology</institution>, <institution>Lomonosov Moscow State University</institution>, <postal-code>119991</postal-code>
<city>Moscow</city>, <country country="RU">Russia</country>
</aff><aff id="aff5">
<label>&#9661;</label>
<institution content-type="dept">Department
of Computational Biology</institution>, <institution>Sirius University
of Science and Technology</institution>, <postal-code>354340</postal-code>
<city>Sirius</city>, <country country="RU">Russia</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>philipp.tsvetkov@univ-amu.fr</email>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>15</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17485</fpage><lpage>17498</lpage><history><date date-type="received"><day>10</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>18</day><month>7</month><year>2025</year></date><date date-type="online"><day>15</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-15"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-15">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c01008.pdf"/><abstract><p>Microtubule targeting
agents (MTAs) constitute a vital category
of tubulin-binding compounds deployed across anticancer therapies.
Despite the array of MTA drugs developed by pharmaceutical entities,
the quest for novel efficacious molecules continues unabated. We unveil
an innovative in vitro MTA screening methodology employing nano-differential
scanning fluorimetry (nanoDSF), presenting distinct advantages over
known assays. This novel approach not only assesses compound-tubulin
binding but also quantitatively analyzes its impact on tubulin polymerization,
facilitating structure&#8211;activity relationship discovery. The
proposed nanoDSF assay was rigorously validated using the Prestwick
Chemical Library, which encompasses 1520 approved compounds, successfully
identifying all previously known MTAs. This screening has unearthed
potential antitubulin agents among drugs currently utilized for unrelated
medical conditions, offering insights into their mechanisms of action
in inhibiting cancer cell proliferation and/or inducing cytotoxicity.
Finally, we have identified a previously unrecognized structure&#8211;activity
relationship within the carbendazim and phenothiazine drug clusters,
providing valuable insights for the rational optimization of compounds
from these families. These discoveries open new opportunities for
drug repositioning of the newly identified MTAs and significantly
streamline the screening process of large chemical libraries for MTAs
with novel chemical scaffolds.</p></abstract><abstract abstract-type="graphical"><graphic position="float" orientation="portrait" xlink:href="jm5c01008_0007.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic id="tgr1" position="float" orientation="portrait" xlink:href="jm5c01008_0005.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>Cancerop&#244;le PACA</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100006331</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c01008</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c01008</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>20943ca5a0a77087526009b2cbb533330a94c3341061ffcef5431717aa9f9da6</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>Microtubules (MT), polymeric structures
composed of tubulin heterodimers,
possess the dynamic ability to elongate or shorten (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>A) in response to environmental
shifts. The dynamic behavior of MTs is essential for cell motility
and division, playing key roles in cytoskeletal rearrangement during
cell migration and the accurate positioning of chromosomes during
mitosis. This necessitates a sophisticated level of control over the
MT dynamics. To achieve such precise regulation, cells have developed
a complex network of microtubule-associated proteins (MAPs) that meticulously
orchestrate the dynamics of MTs.<xref rid="ref1" ref-type="bibr"/> Any disruption
in this fine-tuned process can adversely affect cell migration and
block mitosis and thus potentially be fatal for the cell. This explains
why MT dynamics has become the focus of a wide range of pharmacological
agents.</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Monitoring tubulin polymerization with nano-differential scanning
fluorimetry (nanoDSF). (A) Different stages of tubulin polymerization
in MTs. (B,C) Polymerization and denaturation of tubulin at different
tubulin concentrations followed by nanoDSF; the inset represents tubulin
denaturation followed by nanoDSF in the nonpolymerizing buffer. (D)
Transmission electron microscopy (TEM) of tubulin at different temperatures.
(E) Polymerization and denaturation of tubulin at different tubulin
concentrations followed by turbidimetry. (F) Structures of mebendazole
(MBZ), vinblastine (VBL), and taxol (TXL) complex with tubulin heterodimer
visualized from structures with PDB IDs: <ext-link xlink:href="5J2T" ext-link-type="PDB">5J2T</ext-link>, <ext-link xlink:href="7OGN" ext-link-type="PDB">7OGN</ext-link>, and <ext-link xlink:href="8UTN" ext-link-type="PDB">8UTN</ext-link>. (G&#8211;I) Polymerization and denaturation
of tubulin in the presence of different concentrations of MBZ, VBL,
and TXL, respectively, followed by nanoDSF. (J&#8211;L) Dependence
of the temperatures of polymerization (<italic toggle="yes">T</italic>
<sub>poly</sub>), depolymerization (<italic toggle="yes">T</italic>
<sub>depoly</sub>), and denaturation
(<italic toggle="yes">T</italic>
<sub>m</sub>) of tubulin from the concentration
of MBZ, VBL, and TXL, respectively. (M&#8211;O) Isothermal titration
calorimetry (ITC) curves of tubulin titration by MBZ, VBL, and TXL,
respectively, in the polymerization buffer.</p></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c01008_0001.jpg"/></fig><p>Microtubule targeting agents (MTAs) are a class of tubulin-binding
compounds that are used not only for cancer treatment but also as
anthelmintic, antibacterial, and antifungal drugs. Moreover, recently,
MTA administration was proposed as a new strategy for the therapy
of neurodegenerative diseases.<named-content content-type="bibref-group">
<xref rid="ref2" ref-type="bibr"/>,<xref rid="ref3" ref-type="bibr"/>
</named-content> The MTA interaction
with tubulin significantly impacts MT dynamics, thus perturbing vital
cellular processes. MTAs differ by their binding sites on tubulin<named-content content-type="bibref-group">
<xref rid="ref4" ref-type="bibr"/>,<xref rid="ref5" ref-type="bibr"/>
</named-content> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>F) and are
grouped in two classes by their ability to induce or inhibit MT formation.
The first MTAs with anticancer activity were originally obtained from
plants<xref rid="ref6" ref-type="bibr"/> and were subsequently subjected
to chemical modifications to yield new compounds with superior anticancer
properties. While pharmaceutical companies have developed various
MTA anticancer drugs, the demand for new molecules remains high, driving
researchers to explore additional natural sources of MTAs.<xref rid="ref7" ref-type="bibr"/> These new compounds should exhibit increased
specificity and broader efficacy across different tumor types and
should be capable of overcoming drug resistance observed in certain
tumors, which may arise from MTA interplay with MAPs.<named-content content-type="bibref-group">
<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>
</named-content> Structure-based rational design of MTAs continues to play a crucial
role in drug discovery.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content> However, small chemical
modifications of existing drugs often fail to produce MTAs with significantly
different characteristics due to their shared scaffolds. Therefore,
identifying MTAs with potentially superior anticancer properties requires
screening large and structurally diverse libraries of chemical compounds.</p><p>There are several molecular screening assays based on different
biophysical methods that allow for identification of the interaction
between a target protein and potential binders. Among them, the thermal
shift assay (TSA) has become widely used for early stage drug discovery
in the last years because it is accessible (RT-PCR equipment is sufficient)
and is high throughput (adapted for 96, 384, and 1536-well plates)
with a low material consumption.<xref rid="ref12" ref-type="bibr"/> This
technique facilitates the assessment of protein thermostability (melting
or denaturation temperature, <italic toggle="yes">T</italic>
<sub>m</sub>) in the
presence of screening compounds, thereby providing evidence of an
interaction. However, like many molecular assays, it generates a certain
number of false positive and false negative results. This phenomenon
arises because, first, not all interactions between the protein and
compounds lead to a significant change in protein thermostability,
as detected by TSA, and, second, not every interaction impacts the
biological process regulated by the protein, which is the intended
target of new drug therapies. This is especially relevant for tubulin,
which possesses multiple ligand-binding sites. Consequently, there
is no direct correlation between the extent of tubulin stabilization
by a compound and its efficacy as a polymerization inhibitor or promoter.
Thus, molecular screening assays that not only demonstrate tubulin&#8211;compound
interactions but also elucidate the effect of the compound on tubulin
polymerization (the specific process targeted) are essential for the
efficient discovery of MTAs.</p><p>To address these challenges, we
introduce an <italic toggle="yes">in vitro</italic> functional MTA screening methodology
utilizing nanoDSF. Unlike RT-PCR-based
assays, nanoDSF does not require fluorescent dyes as it monitors the
intrinsic fluorescence of proteins. Remarkably, this approach enables
a dual readout, allowing simultaneous detection of both tubulin stabilization
by the compound and its effect on tubulin polymerization. We applied
the nanoDSF screening assay to the Prestwick Chemical Library (PCL),
which comprises 1520 approved compounds. This application not only
validated the assay with known MTAs contained within the library but
also led to the identification of approximately 100 compounds demonstrating
MTA activity.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Monitoring Tubulin Polymerization
Using Nano-Differential Scanning
Fluorimetry</title><p>To monitor tubulin polymerization, we used a
nanoDSF instrument from NanoTemper Technologies, which enables tracking
of the protein&#8217;s intrinsic fluorescence at 330 and 350 nm across
a temperature range of 15&#8211;95 &#176;C. The ratio of these two
signals (<italic toggle="yes">F</italic>
<sub>350</sub>/<italic toggle="yes">F</italic>
<sub>330</sub>) reflects the exposure of the protein&#8217;s tryptophan side-chain
aromatic groups to the solvent, allowing for the observation of protein
denaturation upon heating the sample. We have noticed that the dimerization
interface of tubulin contains several tryptophan residues, potentially
enabling the use of nanoDSF not only to monitor tubulin denaturation
but also to observe the formation of MTs. To test this hypothesis,
we subjected tubulin samples at varying concentrations to heating
using nanoDSF in a polymerization buffer, wherein tubulin has the
capability to polymerize upon reaching physiological temperatures
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B,C). At a
low subcritical concentration of tubulin, we detected only a single
transition around 62 &#176;C, indicative of tubulin denaturation denoted
further as <italic toggle="yes">T</italic>
<sub>m</sub>. Consistently, at higher
concentrations of tubulin, two additional transitions emerged on the
thermogram. The first transition, occurring between 26 and 39 &#176;C
(depending on tubulin concentration), displayed a signal opposite
that of tubulin denaturation, suggesting that tryptophan side-chain
aromatic groups were concealed from the solvent rather than exposed.
This event most probably corresponds to tubulin polymerization. The
subsequent transition, occurring between 50 and 55 &#176;C, matched
the magnitude of signal change of the first transition but was opposite
in direction, strongly suggesting it correlates with the depolymerization
of MTs. These transitions are also accompanied by changes in sample
turbidity at 350 nm, with an increase followed by a decrease, returning
to baseline around 55 &#176;C (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>E). The polymer state of tubulin under nanoDSF experimental
conditions was confirmed using TEM at different temperatures (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>D), thus validating
nanoDSF as a tool to study the impact of compounds on tubulin polymerization.
Henceforth, we denote the temperatures corresponding to the minima
and maxima of the first derivative of the <italic toggle="yes">F</italic>
<sub>350</sub>/<italic toggle="yes">F</italic>
<sub>330</sub> ratio as the apparent temperatures
of tubulin polymerization (<italic toggle="yes">T</italic>
<sub>poly</sub>) and
depolymerization (<italic toggle="yes">T</italic>
<sub>depoly</sub>), respectively.</p><p>Given that tubulin has multiple binding sites influencing its polymerization,
we evaluated the interaction of tubulin with three MTAs&#58872;Vinblastine
(VBL), Taxol (TXL), and Mebendazole (MBZ)&#58872;each binding to distinct
sites (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>F).
This was done to assess the capability of the nanoDSF assay to detect
interactions between tubulin and MTAs. Therefore, tubulin samples
in the presence of increasing concentrations of MBZ, VBL, and TXL
were subjected to heating from 15 to 80 &#176;C using the nanoDSF
instrument. This induced markedly distinct alterations in tubulin
polymerization and denaturation profiles (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>G&#8211;I). A gradual increase in MBZ concentration
resulted in a notable shift of <italic toggle="yes">T</italic>
<sub>poly</sub> to
higher temperatures without affecting <italic toggle="yes">T</italic>
<sub>depoly</sub> and <italic toggle="yes">T</italic>
<sub>m</sub> (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>G,J), until MBZ reached a concentration of
100 &#956;M. At this concentration, MBZ entirely inhibited MT formation,
resulting in the disappearance of the first two transitions (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>G, yellow curve).</p><p>Contrary to MBZ, VBL is able not only to inhibit tubulin polymerization
in substoichiometric amounts but also to decrease the temperature
of depolymerization (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>H,K). VBL is known to sequester tubulin into spiral structures.
Therefore, the observed changes in <italic toggle="yes">T</italic>
<sub>poly</sub> and <italic toggle="yes">T</italic>
<sub>depoly</sub> values and the shallower
peak slopes may indicate structural transitions between MTs and spirals
rather than dimers. This also explains the increase in the height
of the denaturation peak since it would induce the exposure to the
solvent of tryptophans not only from the tubulin core but also from
the dimerization interface. Moreover, the marked increase in the denaturation
temperature may not result directly from ligand binding but rather
from mutual stabilization of tubulin dimers when arranged within spiral
structures.</p><p>Unlike MBZ and VBL, TXL&#58872;known to promote
MT formation&#58872;shifts <italic toggle="yes">T</italic>
<sub>poly</sub> and <italic toggle="yes">T</italic>
<sub>depoly</sub> in opposite directions (refer to <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>I,L). At a certain
TXL concentration, the
characteristic transitions become indistinguishable: <italic toggle="yes">T</italic>
<sub>poly</sub> drops below 15 &#176;C, while the depolymerization
transition merges with the denaturation peak. Thus, similarly to VBL,
high concentrations of TXL lead to an increase in the height of the
denaturation peak, likely reflecting the unfolding of tubulin that
remains assembled in MTs at the onset of denaturation. Despite this
similarity, the denaturation profiles of tubulin differ markedly between
TXL and VBL. Specifically, a detailed examination of tubulin denaturation
peaks with increasing concentrations of VBL reveals a sequence where
initially, the peak&#8217;s magnitude decreases, followed by the
peak becoming asymmetric, and ultimately, it increases in amplitude
and shifts to higher temperatures. In contrast, TXL leads to a gradual
increase in both the amplitude and <italic toggle="yes">T</italic>
<sub>m</sub> of
tubulin&#8217;s symmetric denaturation peak. This may reflect differences
in site accessibility,<xref rid="ref5" ref-type="bibr"/> which in turn could
influence the dynamics of compound exchange between free and bound
states,<xref rid="ref13" ref-type="bibr"/> thereby differentially affecting
tubulin denaturation.</p><p>Ultimately, the apparent affinity constants
of compounds could
be independently estimated by analyzing both the <italic toggle="yes">T</italic>
<sub>m</sub> shift<xref rid="ref14" ref-type="bibr"/> and the alterations
in fluorescence signal<xref rid="ref15" ref-type="bibr"/> at 15 &#176;C,
which is particularly advantageous under experimental conditions where
conventional reference methods, like ITC, are ineffective (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>M&#8211;O). Moreover,
the nanoDSF assay is easier to set up and requires significantly less
material than ITC.</p></sec><sec id="sec2.2"><title>Application of Nano-Differential Scanning
Fluorimetry for Microtubule
Targeting Agent Screening</title><p>Thus, tracking temperature-induced
tubulin polymerization with nanoDSF enables the detection of shifts
in the polymerization temperature (&#916;<italic toggle="yes">T</italic>
<sub>poly</sub>) across a broad concentration range with high sensitivity. This
approach facilitates the qualitative assessment of MTAs&#8217; effects
on tubulin polymerization, allowing for their comparative evaluation
based on this criterion. Additionally, further heating reveals the
impact of MTAs on tubulin&#8217;s thermostability (&#916;<italic toggle="yes">T</italic>
<sub>m</sub>). By measuring these two distinct parameters,
the first directly related to the tubulin function targeted by MTAs
and the second reflecting the structural influence of MTAs on tubulin,
this approach emerges as highly promising for MTA screening. Advanced
nanoDSF instruments, such as the automated Prometheus NT.Plex, are
equipped to conduct high-throughput screening of chemical libraries
for compounds targeting tubulin. To evaluate the efficacy of our novel
MTA screening methodology, we applied it, as a proof of concept, to
the PCL, which comprises 1520 approved drugs (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>A&#8211;C). Since <italic toggle="yes">T</italic>
<sub>poly</sub> is highly sensitive to tubulin concentration (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>B,C), each run included
a control sample, and the polymerization temperature shifts (&#916;<italic toggle="yes">T</italic>
<sub>poly</sub>) were calculated relative to this control.
This approach helped to minimize the variability of &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> values across experiments. Notably, <italic toggle="yes">T</italic>
<sub>poly</sub> among 67 control samples followed a normal
distribution, with a standard deviation of 0.5 &#176;C, while the
standard deviation of <italic toggle="yes">T</italic>
<sub>poly</sub> in runs without
hits containing one control and 23 molecules was twice as low, at
just 0.25 &#176;C.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>NanoDSF screening of PCL of 1520 approved compounds. (A)
NanoDSF
screening workflow. (B) Results of PCL screening. Red dots represent
sorted data points. (C) Distributions of &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> and &#916;<italic toggle="yes">T</italic>
<sub>m</sub> values
represented as 1D histograms and 2D density plot. (D) &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> histogram and its fitting with Laplace
distribution. (E) 2D distributions of &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> and &#916;<italic toggle="yes">T</italic>
<sub>m</sub> values of hits
with their therapeutic classes (some hits out of plot range, see <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Supporting Information tables</ext-link> for &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> and &#916;<italic toggle="yes">T</italic>
<sub>m</sub> values for all hits). (F) Distribution of hits in therapeutic classes.
(G) Known primary targets of hits. (H,I) IC<sub>50</sub> of hits for
U87MG cancer cell line and its distribution. (J) 2D distributions
of absolute value of |&#916;<italic toggle="yes">T</italic>
<sub>poly</sub>| and
IC<sub>50</sub> of hits (orange points have negative &#916;<italic toggle="yes">T</italic>
<sub>poly</sub>).</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c01008_0002.jpg"/></fig><p>We observed that in the presence of 20 compounds (1.3% of PCL),
tubulin exhibited no polymerization, suggesting either a complete
inhibition of MT formation or the initiation of MT formation at temperatures
below 15 &#176;C. These compounds are henceforth categorized as strong
hits. Among these, nine are already known as MTAs (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), three are suspected of having
MTA activity (Auranofin (AUF), Ebselen (EBS), and Riboflavin (RBF)),
and eight (Aprepitant (APT), Benzarone (BZ), Benzbromarone (BZB),
Benziodarone (BZI), Bithionol (BTN), Hexachlorophene (HCP), Nifedipine
(NFD), and Nisoldipine (NSD)) are newly identified as exhibiting MTA
activity, previously unreported. For the remaining 1500 drugs, tubulin
polymerization occurred, enabling their classification based on two
metrics: &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> and &#916;<italic toggle="yes">T</italic>
<sub>m</sub>. The initial findings, along with 1D and 2D
distributions of these metrics, are depicted in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>B&#8211;D with standard deviation equal
to 0.7 and 0.2 &#176;C for &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> and &#916;<italic toggle="yes">T</italic>
<sub>m</sub>, respectively. Both values
demonstrate Laplace distribution; compounds causing a &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> shift greater than 2 &#176;C were designated
as hits with <italic toggle="yes">p</italic> &lt; 0.0004. Those with a 1 &#176;C
&lt; &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> &lt; 2 &#176;C are also
considered potential MTAs, termed weak hits (<italic toggle="yes">p</italic> &lt;
0.02), meriting further investigation.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>List of
Drugs from PCL with the Most
Important Effect on Tubulin Polymerization</title></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">Name</th><th align="center" colspan="1" rowspan="1">Therapeutic class</th><th align="center" colspan="1" rowspan="1">Targets</th><th align="center" colspan="1" rowspan="1">Impact on MTs</th><th align="center" colspan="1" rowspan="1">Cancer
treatment</th></tr></thead><tbody><tr><td colspan="5" align="center" rowspan="1">
<bold>Known MTAs</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Colchicine</td><td align="left" colspan="1" rowspan="1">metabolism</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">prevents MT assembly and thereby disrupts inflammasome activation<xref rid="ref37" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">derivatives regarded as potential
chemotherapy drugs<xref rid="ref83" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Docetaxel</td><td align="left" colspan="1" rowspan="1">oncology</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">disrupts normal MT dynamics and thereby stops cell division<xref rid="ref84" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">chemotherapy agent utilized in
various cancers<xref rid="ref85" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Fenbendazole</td><td align="left" colspan="1" rowspan="1">infectology metabolism</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">moderate affinity to mammalian tubulin<xref rid="ref48" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">moderate antineoplastic activity<xref rid="ref48" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Mebendazole</td><td align="left" colspan="1" rowspan="1">infectology
metabolism</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">selectively inhibits
tubulin polymerization via interaction
with colchicine-binding site of &#946;-tubulin&#160;<xref rid="ref86" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">repositioned as
a prospective anticancer agent<xref rid="ref47" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Paclitaxel</td><td align="left" colspan="1" rowspan="1">oncology</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">stabilizes the MT polymer and protects it from
disassembly<xref rid="ref87" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">anticancer
drug<xref rid="ref88" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Podophyllotoxin</td><td align="left" colspan="1" rowspan="1">metabolism</td><td align="left" colspan="1" rowspan="1">tubulin</td><td align="left" colspan="1" rowspan="1">prevents polymerization
of tubulin by binding to colchicine
site<xref rid="ref89" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">antitumor, derivatives
applied in chemotherapy<xref rid="ref90" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Dienestrol</td><td align="left" colspan="1" rowspan="1">endocrinology</td><td align="left" colspan="1" rowspan="1">ER&#945;,
ER&#946;</td><td align="left" colspan="1" rowspan="1">inhibits MT assembly in vitro by binding to
the site analogous
to the colchicine site<xref rid="ref26" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">carcinogenic<xref rid="ref91" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Hexestrol</td><td align="left" colspan="1" rowspan="1">endocrinology oncology</td><td align="left" colspan="1" rowspan="1">ER&#945;,
ER&#946;</td><td align="left" colspan="1" rowspan="1">inhibits MT assembly in vitro by binding to
the site analogous
to the colchicine site<xref rid="ref26" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">carcinogenic<xref rid="ref92" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiomersal</td><td align="left" colspan="1" rowspan="1">infectology</td><td align="left" colspan="1" rowspan="1">InsP<sub>3</sub>R</td><td align="left" colspan="1" rowspan="1">inhibits tubulin polymerization in vitro<xref rid="ref27" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">induces apoptosis in some cancer
cell lines<xref rid="ref93" ref-type="bibr"/>
</td></tr><tr><td colspan="5" align="center" rowspan="1">
<bold>Suspected
for MTA activity</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Auranofin</td><td align="left" colspan="1" rowspan="1">metabolism</td><td align="left" colspan="1" rowspan="1">NF-&#954;B kinase &#946;;
PRDX5</td><td align="left" colspan="1" rowspan="1">inhibits phagocytosis which could be linked to
MT modulation<xref rid="ref29" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">cytotoxic
to mutant p53 cancer cells<xref rid="ref45" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Ebselen</td><td align="left" colspan="1" rowspan="1">metabolism central nervous system
(CNS)</td><td align="left" colspan="1" rowspan="1">AChE, SEH</td><td align="left" colspan="1" rowspan="1">in high doses disrupts
MTs in cells<xref rid="ref32" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">suppresses
cancer cell growth<xref rid="ref33" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Riboflavin</td><td align="left" colspan="1" rowspan="1">metabolism ophthalmology</td><td align="left" colspan="1" rowspan="1">FMN</td><td align="left" colspan="1" rowspan="1">rescues cytoskeletal alterations in patients with
RTD<xref rid="ref34" ref-type="bibr"/>
</td><td align="left" colspan="1" rowspan="1">potential adjuvant
in chemoradiotherapy<xref rid="ref35" ref-type="bibr"/>
</td></tr><tr><td colspan="5" align="center" rowspan="1">
<bold>Newly detected
MTAs</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Aprepitant</td><td align="left" colspan="1" rowspan="1">metabolism</td><td align="left" colspan="1" rowspan="1">NK&#160;1 receptor</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">potential antitumor agent<xref rid="ref40" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzarone</td><td align="left" colspan="1" rowspan="1">rheumatology</td><td align="left" colspan="1" rowspan="1">nonpurine XO; SLC22A12; EYA3</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">inhibits tumor growth in animal model<xref rid="ref36" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Benzbromarone</td><td align="left" colspan="1" rowspan="1">cardiovascular</td><td align="left" colspan="1" rowspan="1">uric acid uptake</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">predicted
as a therapeutic drug for lung adenocarcinoma (LUAD)<xref rid="ref44" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Benziodarone</td><td align="left" colspan="1" rowspan="1">cardiovascular</td><td align="left" colspan="1" rowspan="1">uric acid uptake</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">not used</td></tr><tr><td align="left" colspan="1" rowspan="1">Bithionol</td><td align="left" colspan="1" rowspan="1">dermatology</td><td align="left" colspan="1" rowspan="1">ADCY1</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">synergistic with paclitaxel
in ovarian cancer<xref rid="ref42" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Hexachlorophene</td><td align="left" colspan="1" rowspan="1">infectology</td><td align="left" colspan="1" rowspan="1">G6PDH, SHP2</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">suppresses proliferation in nonsmall
cell lung cancer (NSCLC)
model<xref rid="ref42" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Nifedipine</td><td align="left" colspan="1" rowspan="1">cardiovascular</td><td align="left" colspan="1" rowspan="1">cytochrome P450 3A4</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">reverses drug resistance of cancer cells<xref rid="ref43" ref-type="bibr"/>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Nisoldipine</td><td align="left" colspan="1" rowspan="1">cardiovascular</td><td align="left" colspan="1" rowspan="1">DHP channel</td><td align="left" colspan="1" rowspan="1">unknown</td><td align="left" colspan="1" rowspan="1">not used</td></tr></tbody></table></table-wrap><p>Among both strong and weak hits, we discovered that 30 compounds
are classified within the therapeutic category targeting metabolism;
26 are utilized in infectious diseases, 17 in endocrinology, and 17
in the treatment of CNS disorders (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>E,F). When examining the therapeutic effects
of the drugs that influence tubulin polymerization, we identified
27 compounds with antifungal properties, 19 with antineoplastic effects,
16 with antibacterial activity, and 9 each with anti-inflammatory,
antipsychotic, and anthelmintic effects. As expected, the main known
target of those hits was tubulin; still, more than 75% of hits has
another protein listed as the &#8220;main&#8221; target (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>G). Therefore, tubulin
should also be considered a significant target for these compounds,
which could explain the molecular mechanism of action of some compounds,
or the side effects associated with the clinical use of these molecules.</p><p>To assess whether compounds with MTA activity also demonstrate
cytotoxic effects, cell survival assays were conducted on the human
U87MG glioblastoma cell lines at varying concentrations of some identified
compounds. Our analysis revealed that for approximately 50% of these
compounds (54 molecules), the IC<sub>50</sub> value was less than
40 &#956;M, while for about 20% (19 compounds), it was under 10 &#956;M
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>H&#8211;J, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Tables S1&#8211;S8</ext-link>). The IC<sub>50</sub> values
showed no significant correlation with the change in the tubulin polymerization
temperature (&#916;<italic toggle="yes">T</italic>
<sub>poly</sub>) (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>J).</p></sec><sec id="sec2.3"><title>Structure&#8211;Activity
Relationship of Some Newly Identified
Microtubule Targeting Agents</title><p>Furthermore, we analyzed the
structural similarity among all of the hit compounds. To achieve this,
we initially computed a structure similarity matrix detailing the
pairwise distances between compounds, utilizing &#8220;Morgan Connectivity&#8221;
fingerprints. Subsequently, we derived a cluster hierarchy based on
this matrix (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A) and reorganized the structure similarity matrix in accordance
with the identified clustering, excluding compounds with minimal structural
resemblance (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B, hits with small structural similarity are listed in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S8</ext-link>). This process enabled us to identify
and better visualize several clusters of molecules with analogous
structures within the hits (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A,B). Thus, various small clusters that include both
previously identified and novel MTAs are identified (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A,B,F&#8211;L, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Tables S3&#8211;S7</ext-link>), two prominent clusters
are highlighted, composed of established MT inhibitors: carbendazim
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S2</ext-link>) and phenothiazine (PTZ) derivatives
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>E, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). In the last cluster, we identified
two pairs of molecules, perphenazine (PPZ) and fluphenazine (FPh),
as well as chlorpromazine (CPZ) and triflupromazine (TFZ), wherein
the substitution of a chlorine atom (&#8211;Cl) at the second position
of the PTZ scaffold with a trifluoromethyl group (&#8722;CF<sub>3</sub>) (see <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D)
leads to a significant increase in &#916;<italic toggle="yes">T</italic>
<sub>poly</sub>. To gain deeper understanding of this phenomenon, we employed funnel
metadynamics to simulate the docking of these four molecules, along
with colchicine as a control, into the colchicine binding site of
&#946;-tubulin&#58872;also recognized as the binding site for PTZ
derivatives.<xref rid="ref16" ref-type="bibr"/> The docking of colchicine
to &#946;-tubulin resulted in a center-of-mass position that was
consistent with the X-ray crystallographic data (data not shown).
Next, a comparative analysis of the two pairs of compounds showed
that the introduction of trifluoromethyl groups generally altered
both the position and affinity of the molecules (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>A,B). In the CPZ&#8211;TFZ
pair, the difference was most pronounced, with the trifluoromethyl
group penetrating deep into the protein cavity and &#8220;dragging&#8221;
the entire molecule with it. In the PPZ&#8211;FPh pair, the trifluoromethyl
group also played a key role in forming effective contacts within
the hydrophobic region of the &#946;-sheet near the colchicine binding
site. According to our calculations, the affinity of FPh was significantly
higher than that of PPZ. Comparison of TFZ and FPh suggests that their
inhibition efficiencies arise from different mechanisms: while FPh
exhibits high affinity, TFZ binding leads to substantial rearrangements
in the interfacial interactions between &#945;- and &#946;-tubulin
subunits.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Structure&#8211;activity relationship of some hits. (A) Hierarchical
dendrogram representing chemical clusters of hits. (B) Sorted chemical
similarity matrix for hit compounds that have at least one similar
compound among the hits. (C) Absolute value of &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> of hits: polymerization inhibitors are shown in orange
and promoters in blue bars. Strong hits that completely inhibit tubulin
polymerization are shown in white bars. (D) Structures and &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> of CBZ derivatives. Each next modification
is highlighted in light yellow. (E) Structures and &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> of PTZ derivatives. (F&#8211;L) Tubulin
inhibitors grouped by scaffold similarity, with corresponding structural
formulas. Numbers indicate &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> values where applicable; * denotes compounds with low impact on
tubulin polymerization (nonhits).</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c01008_0003.jpg"/></fig><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Funnel
metadynamics simulation for PTZ derivatives. (A) Funnel
metadynamics simulation of the interactions between compounds PPZ,
FPh, CPZ, and TFZ upon binding with the &#946;-tubulin subunit. The
2D plot represents the free energy profile of compound binding, with
coordinates as follows: the <italic toggle="yes">x</italic>-axis indicates the
distance from the center of mass (COM) of the CLH (as determined by
X-ray data, zero value) to the COM of the compound, while the <italic toggle="yes">y</italic>-axis shows the torsion angle representing the arbitrary
rotation of the compound molecule relative to tubulin within the interaction
plane. Stable binding modes are marked with a red cross. (B) Visualization
of the binding modes of compounds PPZ, FPh, CPZ, and TFZ with corresponding
&#946;-tubulin conformations denoted by red cross minima. The protein
molecules are shown in the cartoon mode, colored in blue and light
pink, while the compound molecules are displayed as spheres with carbon
atoms in gray, chlorine atoms in yellow, and fluorine atoms in light
green. The dashed line represents the position of the CLH COM.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c01008_0004.jpg"/></fig></sec></sec><sec id="sec3"><title>Discussion</title><sec id="sec3.1"><title>New Approach for Microtubule
Targeting Agent Screening</title><p>MTAs are an important class of
compounds widely used in the treatment
of various diseases, including antifungal, antibacterial, antihelminthic,
and antineoplastic therapies. Moreover, there is a growing body of
evidence that MT stabilizing MTAs could be used for treatment of brain
disorders.<named-content content-type="bibref-group">
<xref rid="ref2" ref-type="bibr"/>,<xref rid="ref17" ref-type="bibr"/>
</named-content> Despite MTAs being considered a relatively
old class of anticancer drugs, some of which are perceived as no longer
&#8220;trendy&#8221;, new therapeutic approaches based on MTAs continue
to be proposed for cancer treatment.<xref rid="ref18" ref-type="bibr"/> However,
due to the development of drug resistance and significant side effects
associated with these drugs, there is a constant need for more efficient
and specific compounds that target tubulin polymerization. Numerous
efforts have been made to develop MTA screening methods. In 2016,
the team of Klassen et al. developed an assay of antitubulin drugs
screening based on catch-and-release electrospray ionization mass
spectrometry.<xref rid="ref19" ref-type="bibr"/> They concluded that the
developed assay could be applied for anticancer drug screening and
for ranking the affinities of compounds to tubulin. Still, they did
not apply this new assay to &#8220;real&#8221; approved chemical
libraries. Moreover, the affinities of compounds are not always directly
correlated with the anticancer activity of the molecules. While at
least six distinct binding sites for tubulin inhibitors are currently
known, each influencing tubulin polymerization in different ways,
recent virtual screening studies have expanded the number of potential
binding sites to 27.<xref rid="ref20" ref-type="bibr"/> To validate the
virtual screening findings, the development of the functional MTA
test is still needed. This encouraged the team of Stefano Di Fiore
to develop a SNAP-tag-based screening assay for the analysis of MT
dynamics and cell cycle progression.<xref rid="ref21" ref-type="bibr"/> Unfortunately,
like the previous assay, it was tested only on a small number of molecules;
however, it follows MT functions, making it more appropriate for new
MTA screening. The main disadvantage of the proposed assay is that
it follows the impact of tested compounds in the cells wherein it
is very difficult to separate the direct impact of the molecules on
tubulin polymerization from indirect perturbation of the cellular
cytoskeleton through molecules binding to some other targets that
perturb cell cycle and thus impact the cytoskeleton. Finally, to the
best of our knowledge, until now, there has been no functional high-throughput
assay for MTA screening applied to diverse chemical libraries except
in silico virtual screenings<named-content content-type="bibref-group">
<xref rid="ref22" ref-type="bibr"/>&#8722;<xref rid="ref23" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref24" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref25" ref-type="bibr"/>
</named-content> sometimes followed by further in vitro validation.<xref rid="ref22" ref-type="bibr"/>
</p><p>The new nanoDSF screening assay introduced
in this study not only overcomes the limitations of previous methods
but also introduces additional advantages that are crucial for accurately
determining the mode of action of compounds. First, nanoDSF serves
as an in vitro functional assay within a simplified environment, enabling
the ranking of compounds by their effect on tubulin polymerization,
as indicated by shifts in <italic toggle="yes">T</italic>
<sub>poly</sub>. Second,
nanoDSF incorporates several internal controls that enhance the assay&#8217;s
reliability. The initial fluorescence measurement confirms the correct
tubulin concentration, essential since <italic toggle="yes">T</italic>
<sub>poly</sub> is concentration dependent. Additionally, this assay enables the
determination of tubulin&#8217;s <italic toggle="yes">T</italic>
<sub>m</sub>,
thereby not only calculating &#916;<italic toggle="yes">T</italic>
<sub>m</sub> for each compound but also ensuring the proper folding state of
tubulin at each run. This feature is particularly vital for automated
screenings, where maintaining the stability of such &#8220;fragile&#8221;
proteins as tubulin over extended periods in plates is a key concern.
Furthermore, by employing varying concentrations of compounds, it
is feasible to ascertain the apparent association constants of hits
with tubulin based on both the fluorescence signal at a fixed temperature
and the denaturation temperature shift. Unlike previous MTA screening
assays, we validated our method on a library of 1520 approved compounds
and successfully identified every known MTA in that set&#58872; Colchicine,
Docetaxel, Fenbendazole, Mebendazole, Paclitaxel, Podophyllotoxin,
Albendazole, Griseofulvin, Nocodazole, Oxibendazole, Oxfendazole,
Parbendazole, and Triclabendazole.</p></sec><sec id="sec3.2"><title>Compounds with Highest
Microtubule Targeting Agent Activity</title><p>Through a novel nanoDSF
screening assay, we identified approximately
95 compounds with MTA activity within the PCL. Among these, 20 compounds
fully inhibited temperature-induced tubulin polymerization under the
experimental conditions (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). Some achieved this by directly inhibiting polymerization,
while others promoted polymerization at lower temperatures. Notably,
recognized MTAs such as Paclitaxel, Docetaxel, Podophyllotoxin, Colchicine,
Fenbendazole, and Mebendazole were among those that prevented temperature-induced
polymerization entirely. Additionally, our study confirmed that artificial
estrogens like Hexestrol and Dienestrol, as well as the antiseptic
Thiomersal, also impacted tubulin polymerization, consistent with
previous reports of their direct effects on tubulin.<named-content content-type="bibref-group">
<xref rid="ref26" ref-type="bibr"/>,<xref rid="ref27" ref-type="bibr"/>
</named-content>
</p><p>Over half of the strong hits were identified as MTAs for the
first time through this screening. Among these, Auranofin (AUF), Ebselen
(EBS), and Riboflavin (RBF) had previously been shown to affect the
cytoskeleton despite the absence of direct evidence for tubulin binding.
Thus, AUF, an antirheumatic gold complex, inhibits neutrophil activation
by markedly reducing the number of centriole-associated MTs and obstructing
phagocytosis in human polymorphonuclear leukocytes, likely through
a mechanism that involves MT dysregulation.<named-content content-type="bibref-group">
<xref rid="ref28" ref-type="bibr"/>,<xref rid="ref29" ref-type="bibr"/>
</named-content> AUF is increasingly recognized as a potential anticancer agent;
by serving as an inhibitor of both thioredoxin reductase and proteasome,
it induces oxidative stress and triggers apoptosis in models of NSCLC.<xref rid="ref30" ref-type="bibr"/> EBS, an organoselenium compound that mimics
glutathione peroxidase, has been explored as a neuroprotectant in
ischemia and conditions linked to oxidative stress.<xref rid="ref31" ref-type="bibr"/> Research demonstrates its ability to destabilize MTs in
skin melanocytes and inhibit tumor growth through the suppression
of 6-phosphogluconate dehydrogenase activity.<named-content content-type="bibref-group">
<xref rid="ref31" ref-type="bibr"/>&#8722;<xref rid="ref32" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref33" ref-type="bibr"/>
</named-content> Deficiencies
in RBF (vitamin B2) transport are linked to disturbances in MT dynamics;
however, these disruptions can be alleviated through the administration
of RBF in cellular models.<xref rid="ref34" ref-type="bibr"/> Furthermore,
combining RBF with chemotherapy has been suggested as a strategy to
reduce side effects and enhance therapeutic outcomes.<xref rid="ref35" ref-type="bibr"/>
</p><p>Eight of the identified strong hits were previously
unrecognized
in their association with tubulin, marking them as novel discoveries.
Notably, a family of benzofurans (Benzbromarone (BZB), Benzarone (BZ),
and Benziodarone (BZI) <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>I) has been demonstrated to directly and effectively modulate
tubulin polymerization, aligning with previous findings that BZ inhibits
tumor growth in vitro.<xref rid="ref36" ref-type="bibr"/> Intriguingly,
BZ and BZB both were used in the treatment of gout akin to CLH&#58872;a
well-known MTA. While BZB is believed to act through uric acid reuptake,
CLH disrupts inflammasome assembly at the cytoskeletal level.<named-content content-type="bibref-group">
<xref rid="ref37" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/>
</named-content> The revelation that benzofurans may also interact with MTs introduces
an additional dimension to our understanding of their anticancer and
anti-inflammatory properties. Among the novel MTAs identified is APT,
a GPCR inhibitor is extensively used in chemotherapy to prevent common
side effects like nausea. Remarkably, APT is also attributed with
the antitumor properties of its own.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> BTN and HCP
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>L) are fungicides
from a class of bridged diphenyl compounds with cytotoxic and antiproliferative
action in cancer cell lines.<named-content content-type="bibref-group">
<xref rid="ref41" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>
</named-content> Our findings reveal
that several dihydropyridines, approved for managing angina, also
interfere with MT assembly. Notably, Nifedipine (NFD) and Nisoldipine
(NSD) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>G) demonstrated
the most significant impact on tubulin. While calcium channel blockers
like NFD have been previously noted to enhance the sensitivity of
drug-resistant cancer cell lines to PTX,<xref rid="ref43" ref-type="bibr"/> our research marks the first instance of identifying these medications
as MTAs.</p><p>Collectively, the strong hits identified in this study
present
compelling cases for drug repurposing, echoing the findings of prior
research. Specifically, compounds such as AUF, EBS, APT, BZ, BZB,
and HCP exhibit antitumor activity in vitro.<named-content content-type="bibref-group">
<xref rid="ref33" ref-type="bibr"/>,<xref rid="ref36" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>,<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref44" ref-type="bibr"/>,<xref rid="ref45" ref-type="bibr"/>
</named-content> NFD shows potential
in reversing drug resistance in cancer cells,<xref rid="ref43" ref-type="bibr"/> while RBF and BTN enhance the effectiveness of existing anticancer
drugs.<named-content content-type="bibref-group">
<xref rid="ref35" ref-type="bibr"/>,<xref rid="ref41" ref-type="bibr"/>
</named-content> Additionally, BZI and NFD represent modifications
of molecules with established antineoplastic properties, further underscoring
their potential for repurposing in cancer therapy.</p></sec><sec id="sec3.3"><title>Structure&#8211;Activity
Relationship</title><sec id="sec3.3.1"><title>Carbendazim and Benzofuran Clusters</title><p>Carbendazim derivatives
were characterized (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S2</ext-link>) from a significant
cluster of compounds with varied MTA activity, ranging from the complete
inhibition of tubulin polymerization seen in the presence of MBZ and
FBZ to a spectrum of high, medium, and low inhibitory effects observed
for Albendazole (ABZ, 6.4&#176;C), Nocodazole (NCZ, 6.0&#176;C), Oxfendazole
(OFZ, 3.8&#176;C), Methiazole (MTZ, 2.7&#176;C), Parbendazole (PBZ,
1.8&#176;C), Flubendazole (FLU, 1.4&#176;C), and Oxibendazole (OBZ,
1.3&#176;C) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D). While most of these derivatives are utilized as broad-spectrum
anthelmintic agents targeting the colchicine site on tubulin, PBZ
is employed as an antifungal drug, and only NCZ is used in oncology.
However, most exhibit anticancer potential to varying degrees. Specifically,
MBZ and ABZ have been highlighted as promising anticancer agents,<named-content content-type="bibref-group">
<xref rid="ref46" ref-type="bibr"/>,<xref rid="ref47" ref-type="bibr"/>
</named-content> FBZ has shown moderate antineoplastic activity,<xref rid="ref48" ref-type="bibr"/> OFZ has been found to inhibit cell growth in NSCLC,<xref rid="ref49" ref-type="bibr"/> MTZ enhances the efficacy of gemcitabine in
pancreatic cancer,<xref rid="ref50" ref-type="bibr"/> and FBZ has a putative
action against triple-negative breast cancer.<xref rid="ref51" ref-type="bibr"/> Even OBZ, with the lowest inhibitory effect on tubulin polymerization
among the MBZ derivatives, has been reported to significantly impede
the growth of androgen-independent tumors.<xref rid="ref52" ref-type="bibr"/> Carbendazim itself, along with some of its derivatives,<xref rid="ref53" ref-type="bibr"/> are systemic broad-spectrum fungicides that
also target tubulin.<xref rid="ref54" ref-type="bibr"/> The most potent
inhibitors of tubulin polymerization among its derivatives, MBZ and
FBZ, feature a benzene ring attached at the 11th position of the carbendazim
structure, connected through a sulfur atom or a carbonyl group. Further
analysis reveals that the inhibitory effect on tubulin polymerization,
as indicated by changes in &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> for OBZ, PBZ, and ABZ, significantly improves with the substitution
of carbon atoms at the first position of the aliphatic chain with
sulfur and, to a lesser extent, decreases with substitution by oxygen.</p><p>We also identified a compact cluster of three benzofuran derivatives:
Benzarone (BZ), Benzbromarone (BZB), and Benziodarone (BZI) (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>I, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S2</ext-link>). All three compounds exhibited complete inhibition
of tubulin polymerization. Considering that modification of the phenol
group with bromine and iodine does not diminish the inhibitory properties
of BZ, it suggests that the benzofuran moiety may play a pivotal role
in tubulin polymerization inhibition. Supporting this notion, TCZ,
featuring a Benzothiophene group&#58872;a structure analogous to benzofuran
with the oxygen atom replaced by sulfur&#58872;exhibits the most pronounced
effect on tubulin polymerization within the MCZ cluster (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>H). This hypothesis
is in line with published data on the impact of benzofuran in its
derivatives on tubulin polymerization.<named-content content-type="bibref-group">
<xref rid="ref55" ref-type="bibr"/>,<xref rid="ref56" ref-type="bibr"/>
</named-content> While there
has been no previous report of these compounds exhibiting MTA activity,
BZ has been documented to inhibit the growth of colorectal cancer
cells both in vitro and in vivo.<xref rid="ref36" ref-type="bibr"/> Although
the mechanism of BZ&#8217;s action was suggested to involve its primary
target EYA3 and the inhibition of the EYA3-SIX5-p300 complex, our
results suggest the possibility of a direct effect on MTs as well.
This is supported by observations of BZ leading to a dose-dependent
decrease in cell proliferation and invasion,<xref rid="ref36" ref-type="bibr"/> processes fundamentally reliant on MT dynamics. Additionally, BZB
has been pinpointed as a potential candidate for drug repositioning
in the treatment of LUAD through AI-driven analysis of gene dysregulation.<xref rid="ref44" ref-type="bibr"/> Our findings lend robust support to these insights,
suggesting a potential molecular mechanism behind BZB&#8217;s anticancer
efficacy.</p></sec><sec id="sec3.3.2"><title>Tricyclic Molecules Clusters</title><p>Several
derivatives of
PTZ have been identified to exhibit notable MTA activity (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>, <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">Table S1</ext-link>). While PTZ itself induces a modest shift in tubulin
polymerization temperature (&#916;<italic toggle="yes">T</italic>
<sub>poly</sub>) by 1 &#176;C, its derivatives&#58872;Thiethylperazine (TEP, 1.0&#176;C),
Chlorprothixene (CPX, 1.1&#176;C), Toluidine blue (TB, 1.1&#176;C),
Perphenazine (PPZ, 1.5&#176;C), Methylene Blue (MB, 1.7&#176;C), Chlorpromazine
(CPZ, 1.7&#176;C), Trifluoperazine (TFP, 2.7&#176;C), Flupentixol
(FPX, 3.5&#176;C), Fluphenazine (FPh, 3.7&#176;C), and Triflupromazine
(TFZ, 6.4&#176;C)&#58872;show progressively stronger inhibitory effects
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>E). These
are antipsychotics drugs (except TB and MB) often used in schizophrenia
patients, and there is epidemiological evidence that has linked lower
cancer incidence in schizophrenia patients to long-term medication,
highlighting the anticancer potential of antipsychotics.<xref rid="ref57" ref-type="bibr"/> Notably, only TFP and CPZ have been previously
recognized for their ability to inhibit MT assembly,<named-content content-type="bibref-group">
<xref rid="ref58" ref-type="bibr"/>,<xref rid="ref59" ref-type="bibr"/>
</named-content> yet all these derivatives have been either demonstrated or hypothesized
to possess anticancer properties, despite their primary classification
as CNS therapeutics targeting dopamine receptors. For instance, PPZ
has been highlighted as a potential antitumor agent,<xref rid="ref60" ref-type="bibr"/> CPZ in oral cancer treatment,<xref rid="ref61" ref-type="bibr"/> TFP in suppressing colorectal cancer cell models,<xref rid="ref62" ref-type="bibr"/> FPX as a potential lung cancer treatment,<xref rid="ref63" ref-type="bibr"/> FPh in enhancing cancer cell sensitivity to Halaven,<xref rid="ref64" ref-type="bibr"/> and TFZ has been identified as a selective modulator
affecting the breast cancer cell cycle.<xref rid="ref65" ref-type="bibr"/> While various mechanisms for the anticancer activity of these drugs
have been proposed, our results suggest a direct, shared MTA mechanism
among these structurally related molecules.</p><p>Additionally, this
MTA mechanism might offer an alternative explanation for the pleiotropic
effects observed with PTZ derivatives against Gram-negative bacterial
persister cells<xref rid="ref66" ref-type="bibr"/> and their antitubercular
activity.<named-content content-type="bibref-group">
<xref rid="ref67" ref-type="bibr"/>,<xref rid="ref68" ref-type="bibr"/>
</named-content> Within the screened PTZ derivative family,
there are three pairs of molecules in which the substitution of a
&#8211;Cl group with a &#8211;CF<sub>3</sub> group at the second
position (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D)
markedly enhanced their inhibitory effects on tubulin polymerization.
Specifically, for the CPZ and TFZ pair, the &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> escalated from 1.7 to 6.4 &#176;C; for PPZ and FPh,
it increased from 1.5 to 3.7 &#176;C; and for prochlorperazine and
TFP, it rose from 0.5 to 2.7 &#176;C (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D). The critical contribution of the &#8211;CF<sub>3</sub> group to inhibiting tubulin polymerization is also underscored
by a 1 &#176;C higher &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> observed
for 2-(trifluoromethyl) PTZ compared to PTZ.</p><p>A similar enhancement
in tubulin polymerization inhibition resulting
from the substitution of a &#8211;Cl group with a &#8211;CF<sub>3</sub> group is observed in another pair of molecules, derivatives
of thioxanthene. These differ from PTZ derivatives only by replacement
of a nitrogen atom with carbon in the central ring (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>D). Zuclopenthixol (ZPX), bearing
a &#8211;Cl group at the second position, shows no significant effect
on tubulin polymerization, whereas FPX, featuring a &#8211;CF<sub>3</sub> group, induces a 3.5 &#176;C shift in <italic toggle="yes">T</italic>
<sub>poly</sub>.</p><p>This study also uncovered a group of MTAs among
Dibenzosuberone
(DBS) derivatives (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>F), traditionally recognized as tricyclic antidepressants:
Nortriptyline (NTP), Loratadine (LTD), Protriptyline (PTP), Norcyclobenzaprine
(nCBP), Opipramol (OPP), Clomipramine (CMP), and Asenapine (ANP).
These compounds exhibit a modest effect on tubulin polymerization,
with a &#916;<italic toggle="yes">T</italic>
<sub>poly</sub> of approximately 1
&#176;C. While none of these were previously recognized for influencing
tubulin polymerization, certain members have been noted for their
anticancer activities against prostate<named-content content-type="bibref-group">
<xref rid="ref69" ref-type="bibr"/>,<xref rid="ref70" ref-type="bibr"/>
</named-content> or glioblastoma
cell lines.<xref rid="ref71" ref-type="bibr"/> Additionally, CMP has been
reported to augment the cytotoxicity induced by vinorelbine in human
neuroblastoma cancer cells.<xref rid="ref72" ref-type="bibr"/> The antitubulin
properties of PTZ, Thioxanthene, and DBS derivatives, which are utilized
in CNS treatments and thereby capable of crossing the blood&#8211;brain
barrier, position them as promising candidates for repositioning in
the treatment of brain tumors.</p></sec></sec></sec><sec id="sec4"><title>Conclusions</title><p>In
summary, we have developed a novel nanoDSF assay for screening
MT-targeting agents, compounds widely used in anticancer, antifungal,
and antibacterial therapies. Unlike previous assays, our method evaluates
both compound binding to tubulin and its impact on tubulin polymerization.
We validated this assay using the PCL, comprising 1520 approved compounds,
successfully identifying all known MTAs as hits. This approach also
uncovered new antitubulin drugs among compounds previously associated
with cancer cell proliferation inhibition or cytotoxicity, reaffirming
tubulin as a critical target for anticancer drug development. Our
findings not only pave the way for the drug repositioning of newly
identified MTAs and streamline the search for novel scaffolds within
large chemical libraries but also facilitate the exploration of structure&#8211;activity
relationships, contributing to more efficient rational drug discovery.
We hope to inspire renewed interest in the discovery of anticancer
compounds within the MTA class.</p></sec><sec id="sec5"><title>Experimental
Section</title><sec id="sec5.1"><title>Materials</title><p>Human glioblastoma cells were obtained from
ATCC (Gaithersburg, MD, USA). Compounds used in the cytotoxicity assay
were from PCL, MedChemTronica (Bergk&#228;llav&#228;gen, Sweden),
or Sigma (St Louis, MO, USA).</p></sec><sec id="sec5.2"><title>Tubulin Purification</title><p>Tubulin was purified from lamb
brains by ammonium sulfate fractionation and ion-exchange chromatography
and stored in liquid nitrogen as described.<xref rid="ref73" ref-type="bibr"/> Tubulin concentration was determined at 275 nm with an extinction
coefficient of 109,000 M<sup>&#8211;1</sup> cm<sup>&#8211;1</sup> in 6 M guanidine hydrochloride.</p></sec><sec id="sec5.3"><title>Turbidimetry and Differential
Scanning Fluorimetry Assays</title><p>Aliquots of tubulin were passed
through a larger (1 &#215; 10 cm)
gravity column of Sephadex G25 equilibrated with 20 mM sodium phosphate
buffer, 1 mM EGTA, 10 mM MgCl<sub>2</sub>, 3.4 M glycerol, and 0.1
mM GTP, pH 6.5 (PEMGT buffer) or 20 mM Tris, 1 mM MgCl<sub>2</sub>, 0.1 mM GTP, pH 6.5 for nonpolymerizing conditions. For MTA binding
assays, VBL, MBZ, and TXL were used at concentrations up to 100 &#956;M,
with tubulin at 15 or 10 &#956;M, respectively. Each capillary was
loaded with 10 &#956;L of the sample. Fluorescence and turbidimetry
measurements were performed on a nanoDSF Prometheus NT.Plex system
equipped with backscattering optics from 15 to 80 &#176;C, using 10%
excitation power and a temperature ramp of 1 K/min.</p></sec><sec id="sec5.4"><title>Nano-Differential
Scanning Fluorimetry Screening</title><p>For
nanoDSF screening of 1520 FDA-approved compounds, 50 nL aliquots in
100% DMSO were dispensed into 384-well microplates and stored at &#8722;80
&#176;C. Prior to nanoDSF measurements, 10 &#956;L of 10 &#956;M
tubulin in PEMGT buffer was added to each well in a 24-well lane and
mixed thoroughly by pipetting. The final compound concentration was
approximately 50 &#956;M in 0.5% DMSO. Plates were briefly centrifuged
to eliminate air bubbles, and the samples were transferred to standard
DSF-grade capillaries mounted on a 24-capillary rack. All measurements
were performed on a nanoDSF Prometheus NT.Plex instrument from 20
to 75 &#176;C, with 10% excitation power and a heating rate of 1 K/min.</p></sec><sec id="sec5.5"><title>Isothermal Titration Calorimetry</title><p>Binding of MTA to
tubulin was probed using a MicroCal iTC200 instrument (MicroCal, Northampton,
MA, USA, now part of Malvern Instruments Ltd., Malvern, UK) in PEMGT
buffer. To prevent tubulin polymerization, the cell temperature was
maintained at 10 &#176;C. Tubulin was loaded into the calorimetric
cell at a concentration of 20 &#956;M, and MTA was titrated with
a syringe at 250 &#956;M.</p></sec><sec id="sec5.6"><title>Transmission Electron Microscopy</title><p>Samples were adsorbed
onto 200 mesh Formvar carbon-coated copper grids, stained with 2%
(w/v) uranyl acetate, and blotted to dryness. Grids were observed
using a JEOL JEM-1220 transmission electron microscope operated at
80 kV. Magnifications used range from 60,000&#215; to 120,000&#215;.
To ensure that MTs do not disassemble during adsorption, this step
was performed in a thermostated room at 37 &#176;C. The same step
was performed for grids at 4 and 80 &#176;C.</p></sec><sec id="sec5.7"><title>Cell Culture, Cytotoxicity,
and Proliferation Assays</title><p>Glioblastoma cell culture routines,
viability, and proliferation
assays were performed as previously described.<xref rid="ref74" ref-type="bibr"/> U87MG cells were maintained in complete MEM media supplemented
with 10% FBS and 2 mM <sc>l</sc>-glutamine (Invitrogen, Paris, France).
For cytotoxicity assays, cells were counted and plated in 96-well
flat-bottom plates (50,000 cells/mL, 5000 cells per well). After 24
h, the cells were treated with increasing concentrations of the MTAs
(0, 1, 5, 10, and 20&#8211;40 &#956;M) in a vehicle solution, containing
0.05% DMSO. All concentrations were done in triplicates. The surviving
cells were quantified after 72 h by the tetrazolium bromide MTT-assay,
according to the manufacturer&#8217;s instructions. After cell lysis,
the optical density was measured at 600 nm using a Multiskan MS Thermo
plate reader (LabSystems, Waltham, MA, USA). Cell viability was expressed
as a percentage of survival, using cells treated with the vehicle
solution as 100%, and the IC<sub>50</sub> values were calculated by
using the Chou and Talalay linearization method.<xref rid="ref75" ref-type="bibr"/>
</p></sec><sec id="sec5.8"><title>Funnel Metadynamics</title><p>We employed
three freely available
modern force fields, including Amber19sb. All ligands were parametrized
using acpype, with atom point charges derived from ab initio 6-31G
calculations utilizing psiresp.<xref rid="ref76" ref-type="bibr"/> Additional
parameters were assigned according to the GAFF2 force field. GDP was
parametrized in the same manner. The structure of tubulin alpha was
modeled based on the coordinates from PDB ID <ext-link xlink:href="4o2b" ext-link-type="PDB">4o2b</ext-link>.<xref rid="ref77" ref-type="bibr"/> Protonation states of residues were predicted using PROPKA
and manually verified.<xref rid="ref78" ref-type="bibr"/> The system was
then solvated in a triclinic box with periodic boundary conditions
by using TIP3P water molecules. To neutralize the system and achieve
an ionic strength of 0.15 M, Na<sup>+</sup> and Cl<sup>&#8211;</sup> ions were added. Energy minimization was performed using 5000 steps
of the steepest descent method. The equilibration phase comprised
seven steps. Initially, a 100 ps NVT simulation was conducted, applying
positional restraints of 1000 kJ/(mol nm<sup>2</sup>) to the heavy
atoms. Temperature coupling was maintained with a velocity rescale
thermostat.<xref rid="ref79" ref-type="bibr"/> This was followed by five
rounds of NPT equilibration, each lasting 100 ps, during which restraint
strength was gradually reduced: 1000, 500, 200, 100, and 10 kJ/(mol
nm<sup>2</sup>). Pressure coupling was achieved using a stochastic
barostat.<xref rid="ref80" ref-type="bibr"/>
</p><p>The funnel metadynamics
setup was modeled after the approach described by Raniolo and Limongelli.<xref rid="ref81" ref-type="bibr"/> A metadynamic potential of 0.5 kJ/mol was applied
every 500 steps. Two collective variables were employed: first, the
distance between the COM of CLH in its binding site and a reference
point is 20 &#197; away from its position. This variable projected
the ligand along the funnel line. Second, the perpendicular distance
of the ligand from this line. A correction to the binding free energy
was applied to account for the entropic contribution due to the funnel-shaped
restraint, following the equation provided in Raniolo and Limongelli.<xref rid="ref81" ref-type="bibr"/> The correction factor for the cylinder was calculated
as 1.59 kcal/mol. Final binding free energies were reported with error
estimates, following the method of Bhakat and S&#246;derhjelm,<xref rid="ref82" ref-type="bibr"/> using a statistical analysis window of 1000
ns.</p></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c01008_si_001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ack1"><p>This study was supported
by research funding from
the Canc&#233;rop&#244;le PACA AAP &#8220;Repositionnement de
mol&#233;cules en pr&#233;maturation&#8221; 2023 and Cancerop&#244;le
PACA/Gefluc AAP &#8220;Emergence&#8221; 2021.</p></ack><notes id="notes4" notes-type="data-availability"><p>All data available
upon request.</p></notes><notes id="notes1" notes-type="si"><p>The Supporting
Information is
available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01008?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c01008</ext-link>.<list list-type="simple" id="silist"><list-item><p>PTZ, thioxanthene, and
dibenzosuberane clusters; carbendazim
and coumarone clusters; miconazole cluster; NFD cluster; stilbenoids
clusters; steroids cluster; diphenyls clusters; and nonclustered hits
(<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c01008/suppl_file/jm5c01008_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item></list>
</p></notes><notes id="notes3" notes-type="author-contributions"><p>V.B.: conducted
nanoDSF and cell survival screening. R.L.R.: established the initial
nanoDSF setup, conducted ITC and TEM experiments, and prepared the
related figures. D.A.: purified tubulin for the experiments. C.D.:
managed the chemical library. E.P.: oversaw chemical management and
revise the manuscript. P.R.: performed SAR analysis. X.M.: provided
supervision for the chemical library. F.D.: revised the manuscript.
A.V.G.: designed, executed, and analyzed funnel metadynamics experiments,
interpreted the data, and drafted sections of the manuscript. P.O.T.:
secured funding, conception, and design of the study; supervised the
project; performed data analysis and interpretation; prepared figures;
drafted the manuscript; and revised it thoroughly.</p></notes><notes id="notes2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations</title><def-item><term>ITC</term><def><p>isothermal titration calorimetry</p></def></def-item><def-item><term>MAP</term><def><p>microtubule-associated
protein</p></def></def-item><def-item><term>MT</term><def><p>microtubules</p></def></def-item><def-item><term>MTA</term><def><p>microtubule targeting
agents</p></def></def-item><def-item><term>nanoDSF</term><def><p>nano-differential
scanning fluorimetry</p></def></def-item><def-item><term>PCL</term><def><p>Prestwick Chemical Library</p></def></def-item><def-item><term>TEM</term><def><p>transmission electron microscopy</p></def></def-item><def-item><term>TSA</term><def><p>thermal shift assay</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Bodakuntla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jijumon</surname><given-names>A. S.</given-names></name><name name-style="western"><surname>Villablanca</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gonzalez-Billault</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janke</surname><given-names>C.</given-names></name><article-title>Microtubule-Associated Proteins: Structuring the Cytoskeleton</article-title><source>Trends Cell Biol.</source><year>2019</year><volume>29</volume><fpage>804</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2019.07.004</pub-id><pub-id pub-id-type="pmid">31416684</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Boiarska</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Passarella</surname><given-names>D.</given-names></name><article-title>Microtubule-targeting
agents and neurodegeneration</article-title><source>Drug Discovery
Today</source><year>2021</year><volume>26</volume><fpage>604</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.11.033</pub-id><pub-id pub-id-type="pmid">33279455</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Pellegrini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wetzel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grann&#243;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heaton</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>K.</given-names></name><article-title>Back to the
tubule: microtubule dynamics in Parkinson&#8217;s disease</article-title><source>Cell. Mol. Life Sci.</source><year>2017</year><volume>74</volume><fpage>409</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2351-6</pub-id><pub-id pub-id-type="pmid">27600680</pub-id><pub-id pub-id-type="pmcid">PMC5241350</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Guo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>L.</given-names></name><article-title>An overview of tubulin modulators
deposited in protein data bank</article-title><source>Med. Chem. Res.</source><year>2019</year><volume>28</volume><fpage>927</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1007/s00044-019-02352-2</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Steinmetz</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A. E.</given-names></name><article-title>Microtubule-Targeting
Agents: Strategies To Hijack
the Cytoskeleton</article-title><source>Trends Cell Biol.</source><year>2018</year><volume>28</volume><fpage>776</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2018.05.001</pub-id><pub-id pub-id-type="pmid">29871823</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Barbier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsvetkov</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Breuzard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Devred</surname><given-names>F.</given-names></name><article-title>Deciphering
the molecular
mechanisms of anti-tubulin plant derived drugs</article-title><source>Phytochem. Rev.</source><year>2014</year><volume>13</volume><fpage>157</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1007/s11101-013-9302-8</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Gonz&#225;lez
Garc&#237;a</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Radix</surname><given-names>C.</given-names></name><name name-style="western"><surname>Villard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Breuzard</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mansuelle</surname><given-names>P.</given-names></name><name name-style="western"><surname>Barbier</surname><given-names>P.</given-names></name><etal/><article-title>Myotoxin-3 from the
Pacific Rattlesnake Venom Is a New Microtubule-Targeting Agent</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>8241</fpage><pub-id pub-id-type="doi">10.3390/molecules27238241</pub-id><pub-id pub-id-type="pmid">36500334</pub-id><pub-id pub-id-type="pmcid">PMC9739105</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Devred</surname><given-names>F.</given-names></name><etal/><article-title>Stathmin/Op18 is a novel
mediator of vinblastine activity</article-title><source>FEBS Lett.</source><year>2008</year><volume>582</volume><fpage>2484</fpage><lpage>2488</lpage><pub-id pub-id-type="doi">10.1016/j.febslet.2008.06.035</pub-id><pub-id pub-id-type="pmid">18588888</pub-id><pub-id pub-id-type="pmcid">PMC2837597</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Malesinski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsvetkov</surname><given-names>P. O.</given-names></name><name name-style="western"><surname>Kruczynski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peyrot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Devred</surname><given-names>F.</given-names></name><article-title>Stathmin potentiates
vinflunine and inhibits Paclitaxel activity</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><elocation-id>e0128704</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0128704</pub-id><pub-id pub-id-type="pmid">26030092</pub-id><pub-id pub-id-type="pmcid">PMC4451147</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Steinmetz</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A. E.</given-names></name><article-title>Structure-based
discovery and rational design of microtubule-targeting
agents</article-title><source>Curr. Opin. Struct. Biol.</source><year>2024</year><volume>87</volume><fpage>102845</fpage><pub-id pub-id-type="doi">10.1016/j.sbi.2024.102845</pub-id><pub-id pub-id-type="pmid">38805950</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>M&#252;hlethaler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Milanos</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ortega</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Blum</surname><given-names>T. B.</given-names></name><name name-style="western"><surname>Gioia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Cavalli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Steinmetz</surname><given-names>M. O.</given-names></name><article-title>Rational
Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action</article-title><source>Angew. Chem., Int. Ed. Engl.</source><year>2022</year><volume>61</volume><elocation-id>e202204052</elocation-id><pub-id pub-id-type="doi">10.1002/anie.202204052</pub-id><pub-id pub-id-type="pmid">35404502</pub-id><pub-id pub-id-type="pmcid">PMC9324959</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oerlemans</surname><given-names>R.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>M. R.</given-names></name><article-title>Theory and applications of differential
scanning fluorimetry in early-stage drug discovery</article-title><source>Biophys. Rev.</source><year>2020</year><volume>12</volume><fpage>85</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1007/s12551-020-00619-2</pub-id><pub-id pub-id-type="pmid">32006251</pub-id><pub-id pub-id-type="pmcid">PMC7040159</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Celej</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Dassie</surname><given-names>S. A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bianconi</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Fidelio</surname><given-names>G. D.</given-names></name><article-title>Differential
scanning calorimetry as a tool to estimate binding parameters in multiligand
binding proteins</article-title><source>Anal. Biochem.</source><year>2006</year><volume>350</volume><fpage>277</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2005.12.029</pub-id><pub-id pub-id-type="pmid">16434020</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Bhayani</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Ballicora</surname><given-names>M. A.</given-names></name><article-title>Determination of dissociation constants
of protein
ligands by thermal shift assay</article-title><source>Biochem. Biophys.
Res. Commun.</source><year>2022</year><volume>590</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.12.041</pub-id><pub-id pub-id-type="pmid">34959191</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Niebling</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burastero</surname><given-names>O.</given-names></name><name name-style="western"><surname>B&#252;rgi</surname><given-names>J.</given-names></name><name name-style="western"><surname>G&#252;nther</surname><given-names>C.</given-names></name><name name-style="western"><surname>Defelipe</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gattkowski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Anjanappa</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wilmanns</surname><given-names>M.</given-names></name><name name-style="western"><surname>Springer</surname><given-names>S.</given-names></name><etal/><article-title>FoldAffinity:
binding affinities from nDSF experiments</article-title><source>Sci.
Rep.</source><year>2021</year><volume>11</volume><fpage>9572</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-88985-z</pub-id><pub-id pub-id-type="pmid">33953265</pub-id><pub-id pub-id-type="pmcid">PMC8099913</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Posso</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Domingues</surname><given-names>F. C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Silvestre</surname><given-names>S.</given-names></name><article-title>Development
of Phenothiazine Hybrids with Potential Medicinal Interest: A Review</article-title><source>Molecules</source><year>2022</year><volume>27</volume><fpage>276</fpage><pub-id pub-id-type="doi">10.3390/molecules27010276</pub-id><pub-id pub-id-type="pmid">35011508</pub-id><pub-id pub-id-type="pmcid">PMC8746661</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Varidaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>E. T.</given-names></name><article-title>Repositioning
Microtubule Stabilizing
Drugs for Brain Disorders</article-title><source>Front. Cell. Neurosci.</source><year>2018</year><volume>12</volume><fpage>226</fpage><pub-id pub-id-type="doi">10.3389/fncel.2018.00226</pub-id><pub-id pub-id-type="pmid">30135644</pub-id><pub-id pub-id-type="pmcid">PMC6092511</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Ehteda</surname><given-names>A.</given-names></name><etal/><article-title>Microtubule-Targeting Combined with HDAC Inhibition
Is a Novel Therapeutic
Strategy for Diffuse Intrinsic Pontine Gliomas</article-title><source>Mol. Cancer Ther.</source><year>2023</year><volume>22</volume><fpage>1413</fpage><lpage>1421</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-23-0179</pub-id><pub-id pub-id-type="pmid">37683275</pub-id><pub-id pub-id-type="pmcid">PMC10690044</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Rezaei
Darestani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Winter</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kitova</surname><given-names>E. N.</given-names></name><name name-style="western"><surname>Tuszynski</surname><given-names>J. A.</given-names></name><name name-style="western"><surname>Klassen</surname><given-names>J. S.</given-names></name><article-title>Screening Anti-Cancer Drugs against Tubulin using Catch-and-Release
Electrospray Ionization Mass Spectrometry</article-title><source>J.
Am. Soc. Mass Spectrom.</source><year>2016</year><volume>27</volume><fpage>876</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1007/s13361-016-1360-x</pub-id><pub-id pub-id-type="pmid">26944280</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>M&#252;hlethaler</surname><given-names>T.</given-names></name><etal/><article-title>Comprehensive Analysis
of Binding Sites in Tubulin</article-title><source>Angew. Chem., Int.
Ed. Engl.</source><year>2021</year><volume>60</volume><fpage>13331</fpage><lpage>13342</lpage><pub-id pub-id-type="doi">10.1002/anie.202100273</pub-id><pub-id pub-id-type="pmid">33951246</pub-id><pub-id pub-id-type="pmcid">PMC8251789</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Berges</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kreusch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Di Fiore</surname><given-names>S.</given-names></name><article-title>Toward Discovery
of Novel Microtubule Targeting Agents: A SNAP-tag-Based High-Content
Screening Assay for the Analysis of Microtubule Dynamics and Cell
Cycle Progression</article-title><source>SLAS Discovery</source><year>2017</year><volume>22</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1177/2472555216685518</pub-id><pub-id pub-id-type="pmid">28328318</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Horgan</surname><given-names>M. J.</given-names></name><etal/><article-title>Identification of Novel &#946;-Tubulin Inhibitors
Using a Combined/Approach</article-title><source>J. Chem. Inf. Model.</source><year>2023</year><volume>63</volume><fpage>6396</fpage><lpage>6411</lpage><pub-id pub-id-type="doi">10.1021/acs.jcim.3c00939</pub-id><pub-id pub-id-type="pmid">37774242</pub-id><pub-id pub-id-type="pmcid">PMC10598795</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Niu</surname><given-names>M.-M.</given-names></name><etal/><article-title>Tubulin inhibitors: pharmacophore modeling, virtual
screening and
molecular docking</article-title><source>Acta Pharmacol. Sin.</source><year>2014</year><volume>35</volume><fpage>967</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1038/aps.2014.34</pub-id><pub-id pub-id-type="pmid">24909516</pub-id><pub-id pub-id-type="pmcid">PMC4088285</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>P&#233;rez-Pe&#241;a</surname><given-names>H.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>A.-C.</given-names></name><name name-style="western"><surname>Shevelev</surname><given-names>M.</given-names></name><name name-style="western"><surname>Prota</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Pieraccini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Horvath</surname><given-names>D.</given-names></name><article-title>Computational Approaches
to the Rational Design of
Tubulin-Targeting Agents</article-title><source>Biomolecules</source><year>2023</year><volume>13</volume><fpage>285</fpage><pub-id pub-id-type="doi">10.3390/biom13020285</pub-id><pub-id pub-id-type="pmid">36830654</pub-id><pub-id pub-id-type="pmcid">PMC9952983</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Hadizadeh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ghodsi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mirzaei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A.</given-names></name><article-title>In silico Exploration
of Novel Tubulin Inhibitors: A Combination of Docking and Molecular
Dynamics Simulations, Pharmacophore Modeling, and Virtual Screening</article-title><source>Comput. Math. Methods Med.</source><year>2022</year><volume>2022</volume><fpage>4004068</fpage><pub-id pub-id-type="doi">10.1155/2022/4004068</pub-id><pub-id pub-id-type="pmid">35075369</pub-id><pub-id pub-id-type="pmcid">PMC8783753</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Chaudoreille</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Peyrot</surname><given-names>V.</given-names></name><name name-style="western"><surname>Braguer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Codaccioni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Crevat</surname><given-names>A.</given-names></name><article-title>Qualitative study of the interaction
mechanism of estrogenic
drugs with tubulin</article-title><source>Biochem. Pharmacol.</source><year>1991</year><volume>41</volume><fpage>685</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(91)90067-f</pub-id><pub-id pub-id-type="pmid">1847811</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Parry</surname><given-names>J. M.</given-names></name><article-title>An evaluation
of the use of in vitro tubulin polymerisation, fungal and wheat assays
to detect the activity of potential chemical aneugens</article-title><source>Mutat. Res.</source><year>1993</year><volume>287</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/0027-5107(93)90142-3</pub-id><pub-id pub-id-type="pmid">7683381</pub-id></element-citation></ref><ref id="ref28"><element-citation publication-type="journal" id="cit28"><name name-style="western"><surname>Hafstr&#246;m</surname><given-names>I.</given-names></name><name name-style="western"><surname>Seligmann</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Gallin</surname><given-names>J. I.</given-names></name><article-title>Auranofin affects
early events in human polymorphonuclear neutrophil activation by receptor-mediated
stimuli</article-title><source>J. Immunol.</source><year>1984</year><volume>132</volume><fpage>2007</fpage><lpage>2014</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.132.4.2007</pub-id><pub-id pub-id-type="pmid">6321596</pub-id></element-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>K&#252;hn</surname><given-names>S. H.</given-names></name><name name-style="western"><surname>Gemperli</surname><given-names>M. B.</given-names></name><name name-style="western"><surname>De Beer</surname><given-names>F. C.</given-names></name><article-title>Effect of two gold
compounds on human
polymorphonuclear leukocyte lysosomal function and phagocytosis</article-title><source>Inflammation</source><year>1985</year><volume>9</volume><fpage>39</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1007/BF00915410</pub-id><pub-id pub-id-type="pmid">3920144</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Abdalbari</surname><given-names>F. H.</given-names></name><name name-style="western"><surname>Telleria</surname><given-names>C. M.</given-names></name><article-title>The gold complex
auranofin: new perspectives for cancer
therapy</article-title><source>Discover Oncol.</source><year>2021</year><volume>12</volume><fpage>42</fpage><pub-id pub-id-type="doi">10.1007/s12672-021-00439-0</pub-id><pub-id pub-id-type="pmcid">PMC8777575</pub-id><pub-id pub-id-type="pmid">35201489</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Noguchi</surname><given-names>N.</given-names></name><article-title>Ebselen, a
useful tool for understanding cellular redox biology and a promising
drug candidate for use in human diseases</article-title><source>Arch.
Biochem. Biophys.</source><year>2016</year><volume>595</volume><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2015.10.024</pub-id><pub-id pub-id-type="pmid">27095225</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Kasraee</surname><given-names>B.</given-names></name><etal/><article-title>Ebselen is a new skin
depigmenting agent that inhibits melanin biosynthesis
and melanosomal transfer</article-title><source>Exp. Dermatol.</source><year>2012</year><volume>21</volume><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0625.2011.01394.x</pub-id><pub-id pub-id-type="pmid">22082249</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Feng</surname><given-names>Q.</given-names></name><etal/><article-title>Discovery of Ebselen
as an Inhibitor of 6PGD for Suppressing Tumor
Growth</article-title><source>Cancer Manage. Res.</source><year>2020</year><volume>12</volume><fpage>6921</fpage><lpage>6934</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S254853</pub-id><pub-id pub-id-type="pmcid">PMC7415460</pub-id><pub-id pub-id-type="pmid">32801914</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Niceforo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marioli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Colasuonno</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petrini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Massey</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tartaglia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bertini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Compagnucci</surname><given-names>C.</given-names></name><article-title>Altered cytoskeletal
arrangement in induced pluripotent stem cells and motor neurons from
patients with riboflavin transporter deficiency</article-title><source>Dis. Models Mech.</source><year>2021</year><volume>14</volume><fpage>dmm046391</fpage><pub-id pub-id-type="doi">10.1242/dmm.046391</pub-id><pub-id pub-id-type="pmcid">PMC7927654</pub-id><pub-id pub-id-type="pmid">33468503</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Hassan</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chibber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naseem</surname><given-names>I.</given-names></name><article-title>Vitamin B2:
A promising adjuvant
in cisplatin based chemoradiotherapy by cellular redox management</article-title><source>Food Chem. Toxicol.</source><year>2013</year><volume>59</volume><fpage>715</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.fct.2013.07.018</pub-id><pub-id pub-id-type="pmid">23872133</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>Yang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><article-title>Both a hypoxia-inducible
EYA3 and a histone acetyltransferase p300
function as coactivators of SIX5 to mediate tumorigenesis and cancer
progression</article-title><source>Ann. Transl. Med.</source><year>2022</year><volume>10</volume><fpage>752</fpage><pub-id pub-id-type="doi">10.21037/atm-22-2663</pub-id><pub-id pub-id-type="pmid">35957720</pub-id><pub-id pub-id-type="pmcid">PMC9358513</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Dalbeth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lauterio</surname><given-names>T. J.</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>H. R.</given-names></name><article-title>Mechanism of action of colchicine
in the treatment of gout</article-title><source>Clin. Ther.</source><year>2014</year><volume>36</volume><fpage>1465</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2014.07.017</pub-id><pub-id pub-id-type="pmid">25151572</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Azevedo</surname><given-names>V. F.</given-names></name><name name-style="western"><surname>Kos</surname><given-names>I. A.</given-names></name><name name-style="western"><surname>Vargas-Santos</surname><given-names>A. B.</given-names></name><name name-style="western"><surname>da Rocha Castelar Pinheiro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dos Santos Paiva</surname><given-names>E.</given-names></name><article-title>Benzbromarone
in the treatment of gout</article-title><source>Adv. Rheumatol.</source><year>2019</year><volume>59</volume><fpage>37</fpage><pub-id pub-id-type="doi">10.1186/s42358-019-0080-x</pub-id><pub-id pub-id-type="pmid">31391099</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Wang</surname><given-names>D.-S.</given-names></name><etal/><article-title>Effect of Aprepitant for the Prevention of Chemotherapy-Induced
Nausea
and Vomiting in Women: A Randomized Clinical Trial</article-title><source>JAMA Network Open</source><year>2021</year><volume>4</volume><elocation-id>e215250</elocation-id><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2021.5250</pub-id><pub-id pub-id-type="pmid">33835174</pub-id><pub-id pub-id-type="pmcid">PMC8035650</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Mu&#241;oz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cove&#241;as</surname><given-names>R.</given-names></name><article-title>The Neurokinin-1
Receptor Antagonist Aprepitant: An
Intelligent Bullet against Cancer?</article-title><source>Cancers</source><year>2020</year><volume>12</volume><fpage>2682</fpage><pub-id pub-id-type="doi">10.3390/cancers12092682</pub-id><pub-id pub-id-type="pmid">32962202</pub-id><pub-id pub-id-type="pmcid">PMC7564414</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Ayyagari</surname><given-names>V. N.</given-names></name><name name-style="western"><surname>Diaz-Sylvester</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>T.-H. J.</given-names></name><name name-style="western"><surname>Brard</surname><given-names>L.</given-names></name><article-title>Evaluation of the cytotoxicity
of the Bithionol-paclitaxel combination in a panel of human ovarian
cancer cell lines</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><elocation-id>e0185111</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0185111</pub-id><pub-id pub-id-type="pmid">28931042</pub-id><pub-id pub-id-type="pmcid">PMC5607185</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Fu</surname><given-names>N. J.</given-names></name><etal/><article-title>Hexachlorophene, a selective SHP2 inhibitor, suppresses
proliferation
and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK
and PI3K/AKT signaling pathways</article-title><source>Toxicol. Appl.
Pharmacol.</source><year>2022</year><volume>441</volume><fpage>115988</fpage><pub-id pub-id-type="doi">10.1016/j.taap.2022.115988</pub-id><pub-id pub-id-type="pmid">35307375</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Chiu</surname><given-names>L.-Y.</given-names></name><etal/><article-title>L-type calcium channel
blockers reverse docetaxel and vincristine-induced
multidrug resistance independent of ABCB1 expression in human lung
cancer cell lines</article-title><source>Toxicol. Lett.</source><year>2010</year><volume>192</volume><fpage>408</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2009.11.018</pub-id><pub-id pub-id-type="pmid">19944135</pub-id></element-citation></ref><ref id="ref44"><element-citation publication-type="journal" id="cit44"><name name-style="western"><surname>Huang</surname><given-names>R. X.</given-names></name><etal/><article-title>Lung adenocarcinoma-related
target gene prediction and drug repositioning</article-title><source>Front. Pharmacol.</source><year>2022</year><volume>13</volume><fpage>936758</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.936758</pub-id><pub-id pub-id-type="pmid">36081949</pub-id><pub-id pub-id-type="pmcid">PMC9445420</pub-id></element-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Freire
Boullosa</surname><given-names>L.</given-names></name><etal/><article-title>Auranofin reveals therapeutic anticancer potential
by triggering distinct molecular cell death mechanisms and innate
immunity in mutant p53 non-small cell lung cancer</article-title><source>Redox Biol.</source><year>2021</year><volume>42</volume><fpage>101949</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2021.101949</pub-id><pub-id pub-id-type="pmid">33812801</pub-id><pub-id pub-id-type="pmcid">PMC8113045</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Chai</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>B.-K.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.-J.</given-names></name><article-title>Albendazole
and Mebendazole as Anti-Parasitic
and Anti-Cancer Agents: an Update</article-title><source>Korean J.
Parasitol.</source><year>2021</year><volume>59</volume><fpage>189</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.3347/kjp.2021.59.3.189</pub-id><pub-id pub-id-type="pmid">34218593</pub-id><pub-id pub-id-type="pmcid">PMC8255490</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Pantziarka</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bouche</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meheus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sukhatme</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sukhatme</surname><given-names>V. P.</given-names></name><article-title>Repurposing
drugs in oncology (ReDO)&#58872;Cimetidine as an anti-cancer agent</article-title><source>Ecancermedicalscience</source><year>2014</year><volume>8</volume><fpage>485</fpage><pub-id pub-id-type="doi">10.3332/ecancer.2014.485</pub-id><pub-id pub-id-type="pmid">25525463</pub-id><pub-id pub-id-type="pmcid">PMC4268104</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Dogra</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mukhopadhyay</surname><given-names>T.</given-names></name><article-title>Fenbendazole
acts as a moderate microtubule
destabilizing agent and causes cancer cell death by modulating multiple
cellular pathways</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>11926</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-30158-6</pub-id><pub-id pub-id-type="pmid">30093705</pub-id><pub-id pub-id-type="pmcid">PMC6085345</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>S.</given-names></name><article-title>The anthelmintic
agent oxfendazole inhibits cell growth in non-small cell lung cancer
by suppressing c-Src activation</article-title><source>Mol. Med. Rep.</source><year>2019</year><volume>19</volume><fpage>2921</fpage><lpage>2926</lpage><pub-id pub-id-type="doi">10.3892/mmr.2019.9897</pub-id><pub-id pub-id-type="pmid">30720086</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Florio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Veschi</surname><given-names>S.</given-names></name><name name-style="western"><surname>di Giacomo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pagotto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Carradori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verginelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cirilli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Casulli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grassadonia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tinari</surname><given-names>N.</given-names></name><etal/><article-title>The Benzimidazole-Based Anthelmintic Parbendazole:
A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic
Cancer</article-title><source>Cancers</source><year>2019</year><volume>11</volume><fpage>2042</fpage><pub-id pub-id-type="doi">10.3390/cancers11122042</pub-id><pub-id pub-id-type="pmid">31861153</pub-id><pub-id pub-id-type="pmcid">PMC6966614</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Zhen</surname><given-names>Y.</given-names></name><etal/><article-title>Flubendazole elicits
anti-cancer effects via targeting EVA1A-modulated
autophagy and apoptosis in Triple-negative Breast Cancer</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>8080</fpage><lpage>8097</lpage><pub-id pub-id-type="doi">10.7150/thno.43473</pub-id><pub-id pub-id-type="pmid">32724459</pub-id><pub-id pub-id-type="pmcid">PMC7381743</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Chen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.</given-names></name><article-title>Oxibendazole inhibits prostate cancer
cell growth</article-title><source>Oncol. Lett.</source><year>2017</year><volume>15</volume><fpage>2218</fpage><lpage>2226</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.7579</pub-id><pub-id pub-id-type="pmid">29434928</pub-id><pub-id pub-id-type="pmcid">PMC5776919</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><etal/><article-title>Targeting tubulin protein to combat fungal disease: Design, synthesis,
and its new mechanistic insights of benzimidazole hydrazone derivatives</article-title><source>Int. J. Biol. Macromol.</source><year>2025</year><volume>300</volume><fpage>140226</fpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2025.140226</pub-id><pub-id pub-id-type="pmid">39855516</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Vela-Corc&#237;a</surname><given-names>D.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Vicente</surname><given-names>A.</given-names></name><name name-style="western"><surname>P&#233;rez-Garc&#237;a</surname><given-names>A.</given-names></name><article-title>Analysis of
&#946;-tubulin-carbendazim interaction reveals that binding site
for MBC fungicides does not include residues involved in fungicide
resistance</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>7161</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-25336-5</pub-id><pub-id pub-id-type="pmid">29740047</pub-id><pub-id pub-id-type="pmcid">PMC5940828</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>El-Sayed</surname><given-names>N. F.</given-names></name><etal/><article-title>Design, synthesis, biological evaluation, and molecular docking of
new benzofuran and indole derivatives as tubulin polymerization inhibitors</article-title><source>Drug Dev. Res.</source><year>2022</year><volume>83</volume><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1002/ddr.21880</pub-id><pub-id pub-id-type="pmid">34523738</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Stehrer-Schmid</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>H. U.</given-names></name><article-title>Effects of benzofuran
and seven benzofuran derivatives
including four carbamate insecticides in the in vitro porcine brain
tubulin assembly assay and description of a new approach for the evaluation
of the test data</article-title><source>Mutat. Res.</source><year>1995</year><volume>339</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/0165-1110(94)00015-5</pub-id><pub-id pub-id-type="pmid">7877645</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Hsu</surname><given-names>C.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W.-T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.-H.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>K.-C.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>C.-C.</given-names></name><article-title>Sertindole, an Antipsychotic
Drug,
Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis
In Vitro</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><fpage>11852</fpage><pub-id pub-id-type="doi">10.3390/ijms241411852</pub-id><pub-id pub-id-type="pmid">37511611</pub-id><pub-id pub-id-type="pmcid">PMC10380261</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Rao</surname><given-names>A. G.</given-names></name><name name-style="western"><surname>Cann</surname><given-names>J. R.</given-names></name><article-title>A comparative
study of the interaction of chlorpromazine,
trifluoperazine, and promethazine with mouse brain tubulin</article-title><source>Mol. Pharmacol.</source><year>1981</year><volume>19</volume><fpage>295</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S0026-895X(25)13483-4</pub-id><pub-id pub-id-type="pmid">7231390</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Poffenbarger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuller</surname><given-names>G. M.</given-names></name><article-title>Effects of psychotropic
drugs on neurotubule assembly</article-title><source>J. Neurochem.</source><year>1977</year><volume>28</volume><fpage>1167</fpage><lpage>1174</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1977.tb12305.x</pub-id><pub-id pub-id-type="pmid">874480</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><etal/><article-title>Repurposing of antipsychotics
perphenazine for the treatment of endometrial
cancer</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2020</year><volume>30</volume><fpage>127239</fpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2020.127239</pub-id><pub-id pub-id-type="pmid">32527541</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Jhou</surname><given-names>A.-J.</given-names></name><etal/><article-title>Chlorpromazine, an antipsychotic agent, induces G2/M
phase arrest
and apoptosis via regulation of the PI3K/AKT/mTOR-mediated autophagy
pathways in human oral cancer</article-title><source>Biochem. Pharmacol.</source><year>2021</year><volume>184</volume><fpage>114403</fpage><pub-id pub-id-type="doi">10.1016/j.bcp.2020.114403</pub-id><pub-id pub-id-type="pmid">33388284</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Xia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ran</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>T.</given-names></name><article-title>Antipsychotic Drug
Trifluoperazine Suppresses Colorectal Cancer by Inducing G0/G1 Arrest
and Apoptosis</article-title><source>Front. Pharmacol</source><year>2019</year><volume>10</volume><fpage>1029</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01029</pub-id><pub-id pub-id-type="pmid">31572198</pub-id><pub-id pub-id-type="pmcid">PMC6753363</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Dong</surname><given-names>C.</given-names></name><etal/><article-title>The antipsychotic agent flupentixol is a new PI3K inhibitor
and potential
anticancer drug for lung cancer</article-title><source>Int. J. Biol.
Sci.</source><year>2019</year><volume>15</volume><fpage>1523</fpage><lpage>1532</lpage><pub-id pub-id-type="doi">10.7150/ijbs.32625</pub-id><pub-id pub-id-type="pmid">31337981</pub-id><pub-id pub-id-type="pmcid">PMC6643147</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Cheon</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B. M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. S.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.</given-names></name><article-title>Highly Halaven-resistant
KBV20C Cancer Cells Can Be Sensitized by Co-treatment with Fluphenazine</article-title><source>Anticancer Res.</source><year>2016</year><volume>36</volume><fpage>5867</fpage><lpage>5874</lpage><pub-id pub-id-type="doi">10.21873/anticanres.11172</pub-id><pub-id pub-id-type="pmid">27793910</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Warchal</surname><given-names>S. J.</given-names></name><etal/><article-title>High content phenotypic screening identifies serotonin receptor modulators
with selective activity upon breast cancer cell cycle and cytokine
signaling pathways</article-title><source>Bioorg. Med. Chem.</source><year>2020</year><volume>28</volume><fpage>115209</fpage><pub-id pub-id-type="doi">10.1016/j.bmc.2019.115209</pub-id><pub-id pub-id-type="pmid">31757681</pub-id><pub-id pub-id-type="pmcid">PMC6961118</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Mohiuddin</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>T. V.</given-names></name><name name-style="western"><surname>Orman</surname><given-names>M. A.</given-names></name><article-title>Pleiotropic actions
of phenothiazine
drugs are detrimental to Gram-negative bacterial persister cells</article-title><source>Commun. Biol.</source><year>2022</year><volume>5</volume><fpage>217</fpage><pub-id pub-id-type="doi">10.1038/s42003-022-03172-8</pub-id><pub-id pub-id-type="pmid">35264714</pub-id><pub-id pub-id-type="pmcid">PMC8907348</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Nizi</surname><given-names>M. G.</given-names></name><etal/><article-title>Antitubercular polyhalogenated
phenothiazines and phenoselenazine
with reduced binding to CNS receptors</article-title><source>Eur.
J. Med. Chem.</source><year>2020</year><volume>201</volume><fpage>112420</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112420</pub-id><pub-id pub-id-type="pmid">32526553</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Yano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>L.-S.</given-names></name><name name-style="western"><surname>Weinstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Teh</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>H.</given-names></name><article-title>Steady-state
kinetics and inhibitory action of antitubercular phenothiazines on
mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase
(NDH-2)</article-title><source>J. Biol. Chem.</source><year>2006</year><volume>281</volume><fpage>11456</fpage><lpage>11463</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508844200</pub-id><pub-id pub-id-type="pmid">16469750</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><etal/><article-title>Drug repurposing for cancer treatment through global
propagation with a greedy algorithm in a multilayer network</article-title><source>Cancer Biol. Med.</source><year>2021</year><volume>19</volume><fpage>74</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.20892/j.issn.2095-3941.2020.0218</pub-id><pub-id pub-id-type="pmid">33893730</pub-id><pub-id pub-id-type="pmcid">PMC8762999</pub-id></element-citation></ref><ref id="ref70"><element-citation publication-type="journal" id="cit70"><name name-style="western"><surname>Chang</surname><given-names>H.-T.</given-names></name><etal/><article-title>The mechanism of protriptyline-induced
Ca<sup>2+</sup> movement and
non-Ca<sup>2+</sup>-triggered cell death in PC3 human prostate cancer
cells</article-title><source>J. Recept. Signal Transduction</source><year>2015</year><volume>35</volume><fpage>429</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.3109/10799893.2014.1000464</pub-id><pub-id pub-id-type="pmid">26096164</pub-id></element-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Lin</surname><given-names>W.-Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>M.-C.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>C.-T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.-J.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>C.-M.</given-names></name><name name-style="western"><surname>Shiau</surname><given-names>C.-Y.</given-names></name><article-title>From GWAS to drug
screening: repurposing antipsychotics for glioblastoma</article-title><source>J. Transl. Med.</source><year>2022</year><volume>20</volume><fpage>70</fpage><pub-id pub-id-type="doi">10.1186/s12967-021-03209-2</pub-id><pub-id pub-id-type="pmid">35120529</pub-id><pub-id pub-id-type="pmcid">PMC8815269</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Bilir</surname><given-names>A.</given-names></name><etal/><article-title>Enhancement of vinorelbine-induced
cytotoxicity and apoptosis by
clomipramine and lithium chloride in human neuroblastoma cancer cell
line SH-SY5Y</article-title><source>J. Neuro-Oncol.</source><year>2010</year><volume>100</volume><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1007/s11060-010-0209-6</pub-id><pub-id pub-id-type="pmid">20467784</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Andreu</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Gorbunoff</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Timasheff</surname><given-names>S. N.</given-names></name><article-title>Interaction
of tubulin with bifunctional colchicine analogues: an equilibrium
study</article-title><source>Biochemistry</source><year>1984</year><volume>23</volume><fpage>1742</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1021/bi00303a025</pub-id><pub-id pub-id-type="pmid">6722122</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Chocry</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leloup</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parat</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mess&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kovacic</surname><given-names>H.</given-names></name><article-title>Gemcitabine: An Alternative Treatment
for Oxaliplatin-Resistant Colorectal Cancer</article-title><source>Cancers</source><year>2022</year><volume>14</volume><fpage>5894</fpage><pub-id pub-id-type="doi">10.3390/cancers14235894</pub-id><pub-id pub-id-type="pmid">36497380</pub-id><pub-id pub-id-type="pmcid">PMC9740936</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Chou</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Talalay</surname><given-names>P.</given-names></name><article-title>Quantitative analysis of dose-effect
relationships:
the combined effects of multiple drugs or enzyme inhibitors</article-title><source>Adv. Enzyme Regul.</source><year>1984</year><volume>22</volume><fpage>27</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1016/0065-2571(84)90007-4</pub-id><pub-id pub-id-type="pmid">6382953</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Alenaizan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Sherrill</surname><given-names>C. D.</given-names></name><article-title>Python
implementation of the restrained
electrostatic potential charge model</article-title><source>Int. J.
Quantum Chem.</source><year>2020</year><volume>120</volume><elocation-id>e26035</elocation-id><pub-id pub-id-type="doi">10.1002/qua.26035</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Prota</surname><given-names>A. E.</given-names></name><etal/><article-title>The novel microtubule-destabilizing
drug BAL27862 binds to the colchicine
site of tubulin with distinct effects on microtubule organization</article-title><source>J. Mol. Biol.</source><year>2014</year><volume>426</volume><fpage>1848</fpage><lpage>1860</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2014.02.005</pub-id><pub-id pub-id-type="pmid">24530796</pub-id></element-citation></ref><ref id="ref78"><element-citation publication-type="journal" id="cit78"><name name-style="western"><surname>S&#248;ndergaard</surname><given-names>C. R.</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>M. H. M.</given-names></name><name name-style="western"><surname>Rostkowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>J. H.</given-names></name><article-title>Improved Treatment
of Ligands and Coupling Effects in Empirical Calculation and Rationalization
of pKa Values</article-title><source>J. Chem. Theory Comput.</source><year>2011</year><volume>7</volume><fpage>2284</fpage><lpage>2295</lpage><pub-id pub-id-type="doi">10.1021/ct200133y</pub-id><pub-id pub-id-type="pmid">26606496</pub-id></element-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Bussi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Donadio</surname><given-names>D.</given-names></name><name name-style="western"><surname>Parrinello</surname><given-names>M.</given-names></name><article-title>Canonical sampling through velocity
rescaling</article-title><source>J. Chem. Phys.</source><year>2007</year><volume>126</volume><fpage>014101</fpage><pub-id pub-id-type="doi">10.1063/1.2408420</pub-id><pub-id pub-id-type="pmid">17212484</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Bernetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bussi</surname><given-names>G.</given-names></name><article-title>Pressure control using
stochastic cell rescaling</article-title><source>J. Chem. Phys.</source><year>2020</year><volume>153</volume><fpage>114107</fpage><pub-id pub-id-type="doi">10.1063/5.0020514</pub-id><pub-id pub-id-type="pmid">32962386</pub-id></element-citation></ref><ref id="ref81"><element-citation publication-type="journal" id="cit81"><name name-style="western"><surname>Raniolo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Limongelli</surname><given-names>V.</given-names></name><article-title>Ligand binding free-energy calculations with funnel
metadynamics</article-title><source>Nat. Protoc.</source><year>2020</year><volume>15</volume><fpage>2837</fpage><lpage>2866</lpage><pub-id pub-id-type="doi">10.1038/s41596-020-0342-4</pub-id><pub-id pub-id-type="pmid">32814837</pub-id></element-citation></ref><ref id="ref82"><element-citation publication-type="journal" id="cit82"><name name-style="western"><surname>Bhakat</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#246;derhjelm</surname><given-names>P.</given-names></name><article-title>Resolving the problem of trapped
water in binding cavities:
prediction of host-guest binding free energies in the SAMPL5 challenge
by funnel metadynamics</article-title><source>J. Comput.-Aided Mol.
Des.</source><year>2017</year><volume>31</volume><fpage>119</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/s10822-016-9948-6</pub-id><pub-id pub-id-type="pmid">27573983</pub-id><pub-id pub-id-type="pmcid">PMC5239820</pub-id></element-citation></ref><ref id="ref83"><element-citation publication-type="journal" id="cit83"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Mondhe</surname><given-names>D. M.</given-names></name><article-title>Potential
anticancer role of colchicine-based
derivatives: an overview</article-title><source>Anticancer Drugs</source><year>2017</year><volume>28</volume><fpage>250</fpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000000464</pub-id><pub-id pub-id-type="pmid">28030380</pub-id></element-citation></ref><ref id="ref84"><element-citation publication-type="journal" id="cit84"><name name-style="western"><surname>Cheetham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petrylak</surname><given-names>D. P.</given-names></name><article-title>Tubulin-targeted agents including
docetaxel and cabazitaxel</article-title><source>Cancer J.</source><year>2013</year><volume>19</volume><fpage>59</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e3182828d38</pub-id><pub-id pub-id-type="pmid">23337758</pub-id></element-citation></ref><ref id="ref85"><element-citation publication-type="journal" id="cit85"><name name-style="western"><surname>Cortes</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.</given-names></name><article-title>Docetaxel</article-title><source>J. Clin. Oncol.</source><year>1995</year><volume>13</volume><fpage>2643</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1200/JCO.1995.13.10.2643</pub-id><pub-id pub-id-type="pmid">7595719</pub-id></element-citation></ref><ref id="ref86"><element-citation publication-type="journal" id="cit86"><name name-style="western"><surname>Lacey</surname><given-names>E.</given-names></name><article-title>Mode of action
of benzimidazoles</article-title><source>Parasitol. Today</source><year>1990</year><volume>6</volume><fpage>112</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1016/0169-4758(90)90227-U</pub-id><pub-id pub-id-type="pmid">15463312</pub-id></element-citation></ref><ref id="ref87"><element-citation publication-type="journal" id="cit87"><name name-style="western"><surname>Yang</surname><given-names>C.-P. H.</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>S. B.</given-names></name><article-title>Taxol: The First Microtubule Stabilizing
Agent</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><fpage>1733</fpage><pub-id pub-id-type="doi">10.3390/ijms18081733</pub-id><pub-id pub-id-type="pmid">28792473</pub-id><pub-id pub-id-type="pmcid">PMC5578123</pub-id></element-citation></ref><ref id="ref88"><element-citation publication-type="journal" id="cit88"><name name-style="western"><surname>Vyas</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Kadow</surname><given-names>J. F.</given-names></name><article-title>Paclitaxel: a unique tubulin interacting anticancer
agent</article-title><source>Prog. Med. Chem.</source><year>1995</year><volume>32</volume><fpage>289</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/S0079-6468(08)70456-9</pub-id><pub-id pub-id-type="pmid">8577920</pub-id></element-citation></ref><ref id="ref89"><element-citation publication-type="journal" id="cit89"><name name-style="western"><surname>Sackett</surname><given-names>D. L.</given-names></name><article-title>Podophyllotoxin,
steganacin and combretastatin: natural products that bind at the colchicine
site of tubulin</article-title><source>Pharmacol. Ther.</source><year>1993</year><volume>59</volume><fpage>163</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(93)90044-E</pub-id><pub-id pub-id-type="pmid">8278462</pub-id></element-citation></ref><ref id="ref90"><element-citation publication-type="journal" id="cit90"><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><etal/><article-title>Challenges and potential for improving the druggability
of podophyllotoxin-derived
drugs in cancer chemotherapy</article-title><source>Nat. Prod. Rep.</source><year>2021</year><volume>38</volume><fpage>470</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1039/D0NP00041H</pub-id><pub-id pub-id-type="pmid">32895676</pub-id></element-citation></ref><ref id="ref91"><element-citation publication-type="journal" id="cit91"><name name-style="western"><surname>Inano</surname><given-names>H.</given-names></name><etal/><article-title>Promotive effects of diethylstilbestrol, its metabolite (Z,Z-dienestrol)
and a stereoisomer of the metabolite (E,E-dienestrol) in tumorigenesis
of rat mammary glands pregnancy-dependently initiated with radiation</article-title><source>Carcinogenesis</source><year>1993</year><volume>14</volume><fpage>2157</fpage><lpage>2163</lpage><pub-id pub-id-type="doi">10.1093/carcin/14.10.2157</pub-id><pub-id pub-id-type="pmid">8222069</pub-id></element-citation></ref><ref id="ref92"><element-citation publication-type="journal" id="cit92"><name name-style="western"><surname>Cavalieri</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Rogan</surname><given-names>E. G.</given-names></name><article-title>A unified mechanism in the initiation of cancer</article-title><source>Ann. N.Y. Acad. Sci.</source><year>2002</year><volume>959</volume><fpage>341</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2002.tb02105.x</pub-id><pub-id pub-id-type="pmid">11976208</pub-id></element-citation></ref><ref id="ref93"><element-citation publication-type="journal" id="cit93"><name name-style="western"><surname>Kuo</surname><given-names>L. N.</given-names></name><etal/><article-title>Effect of thimerosal
on Ca&#173;(2+) movement and viability in human oral
cancer cells</article-title><source>Hum. Exp. Toxicol.</source><year>2009</year><volume>28</volume><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1177/0960327109106548</pub-id><pub-id pub-id-type="pmid">19661262</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>